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 Cardiovascular disease and subsequent complications, such as 
myocardial infarction (MI), is the leading cause of death within the United States. 
Clinical intervention to reduce cardiac damage following myocardial ischemia is 
limited. Polyunsaturated fatty acids have been linked to an overall beneficial 
effect on cardiovascular health and function. Conjugated linoleic acid (cLA) is an 
18:2 unsaturated fatty acid found within the diet in ruminant meat and dairy 
products. The cis-9 trans-11 isomer of cLA is the most prominent isomer within 
the diet and cLA has been linked to favorable outcomes in numerous disease 
states. The mechanism mediating the effects of cLA are still unclear but 
mitochondria appear to be playing a prominent role. Nitrite (NO2
-) is a dietary 
source of nitric oxide (NO), as it is found within green leafy vegetables and it is 
linked to cardioprotection in ischemia reperfusion injury models. Alterations in 
vi 
mitochondrial function and electron transport chain enzymatic activity have been 
elucidated as the mechanisms mediating nitrite cardioprotection. However, 
recent clinical trials have reported no positive outcome in patients undergoing MI 
who have been supplemented with nitrite. A combination treatment of cLA and 
nitrite preserves cardiac function following MI, highlighting that the interaction 
between dietary constituents may influence cardioprotective effects. In the first 
step of this study, we examine whether the combination treatment of cLA and 
nitrite influenced mitochondrial respiration and electron transport chain activity 
under baseline conditions. In the second step of this study, we examine the 
impact of co-treatment with cLA and nitrite on mitochondrial function following MI 
and aging. Under baseline conditions, we found that co-administration of cLA and 
nitrite decreased mitochondrial respiration and complex III activity. Following MI, 
the co-treatment of cLA and nitrite attenuated MI-induced increases in 
mitochondrial respiration, complex III activity, and hydrogen peroxide levels. 
However, following aging the co-treatment was unable to restore aging induced 
mitochondrial dysfunction. These results demonstrate that in combination the 
dietary constituents, cLA and nitrite, are able to influence mitochondrial function 
under non-injury setting and following MI. Overall, this supports a role of 
mitochondria in the cardioprotective effects mediated by a combination treatment 
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INTRODUCTION: CARDIOVASCULAR DISEASE, MITOCHONDRIA, AND 
NITRATED FATTY ACIDS  
 
Cardiovascular Disease Statistics  
 
 Cardiovascular disease (CVD) is the leading cause of death globally, 
accounting for more than 17.3 million deaths annually and representing an 
economic cost of $863 billion as of 2010 (1). CVD affects 85.6 million Americans 
and represents approximately 31.3% of all deaths in the United States (US) (1). 
The estimated direct and indirect cost of CVD within the US as of 2011 was 
estimated at $320.1 billion and the direct cost of CVD is expected to increase to 
over $918 billion by 2030 (1). Coronary heart disease (CHD) is the most common 
type of CVD, making up approximately half of all CVD deaths. An estimated 15.5 
million US adults have CHD and the morality associated with CHD was 375,295 
in the U.S. in 2011(1). A common complication of CHD is myocardial infarction 
(MI) and the estimated annual incidence of MI is 525,000 new attacks and 
210,000 recurrent attacks within the U.S. (1). 
 Coronary heart disease is the result of atherosclerosis, a progressive 
disease stemming from inflammation of intima of the coronary arteries leading to 
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gradual thickening of the intima (2). Risk factors for coronary artery disease 
include a high level of low density lipoproteins (LDL), high blood cholesterol 
levels, family history, diabetes, obesity, smoking and age. Atherosclerosis can be 
broken down into several stages: 1) endothelial dysfunction, 2) oxidized LDL and 
macrophage accumulation, 3) foam cell formation and smooth muscle 
recruitment, 4) vascularization, 5) necrotic core and 6) plaque rupture. 
Endothelial dysfunction caused by low wall shear stress is a key initiation event 
for atherosclerosis (3) leading to decreased nitric oxide (NO) and increased 
chemokine and pro-inflammatory mediators (4). Increased expression of 
adhesion molecules (5), the scavenger receptor CD-36 (6), and proteoglycans 
(7) lead to recruitment of monocytes and oxidized LDL within the intima. 
Monocytes differentiate into macrophages and ingest oxidized LDL forming foam 
cells. Foam cells secrete pro-inflammatory cytokines and recruit smooth muscle 
cells (3) to the intima which also take up lipids creating a lipid rich core within the 
plaque. Neovascularization of the plaque by leaky vasculature from the 
adventitial vasa vasorum leads to further monocyte recruitment (3) and increases 
plaque size (8). Eventually the plaque forms a necrotic core due to macrophage 
(9), foam cell and smooth muscle cell (3) apoptosis. The loss of smooth muscle 
cell secretion of collagen, elastin, and proteoglycans leads to plaque cap 
thinning. Cap thinning can lead to plaque rupture (10), exposing the 
thromobogenic plaque core to platelets within blood, thereby initiating platelet 
aggregation, vasoconstriction, and fibrin deposition (8), which leads to occlusion 
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of a coronary artery (2). Disruption in blood and oxygen flow to the myocardium 
results in MI, a major healthcare consequence of coronary heart disease.   
 MI is defined as myocardial cell death due to prolonged ischemia and is 
the result of an imbalance between oxygen supply and demand (11). Ischemic 
injury can be divided into three phases: 1) ischemic 2) reperfusion and 3) 
reperfusion repair (12). The lack of oxygen of during ischemia results in 
cardiomyocyte cell death via apoptosis and necrosis (13). Apoptosis is a 
programmed cell death pathway characterized by membrane blebbing, cell 
shrinkage, nuclear fragmentation and chromatin condensation (14). Apoptosis is 
activated via two distinct pathways: the extrinsic and intrinsic pathway. The 
extrinsic pathway is mediated by proinflammatory ligands such as tumor necrosis 
factor alpha (TNF-) and tumor necrosis factor ligand super family member six 
(15) which activate plasma membrane receptors. The intrinsic pathway is 
mediated by release of mitochondrial death factors including cytochrome c, high 
temperature requirement A2 (HtrA2) apoptosis inducing factor and second 
mitochondrial derived activator of caspase (SMAC). The downstream target of 
both the intrinsic and extrinsic pathways is caspase-3, a cysteine protease, which 
degrades proteins and activates deoxyribonucleases (DNases) to degrade 
deoxyribonucleic acid (DNA) (14). Apoptosis is an energy requiring process so 
cardiomyocytes within the border zone of the infarct undergo apoptosis and 
cardiomyocytes within the infarct zone undergo necrosis due to depletion of 
adenosine triphosphate (ATP).  
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 Necrosis involves whole cell swelling and loss of plasma membrane 
integrity (14) resulting from decreased ATP levels needed to maintain ionic 
gradients at the plasma membrane. Upon plasma membrane rupture cellular 
contents initiate an inflammatory response within the myocardium resulting in 
migration of macrophages, monocytes, and neutrophils into the infarct zone (16). 
Macrophages secrete growth factors leading to conversion of fibroblasts to 
myofibroblasts that secrete collagen to preserve ventricular integrity. The hypoxic 
environment occurring during MI sets the stage for cell death and reperfusion of 
ischemic cardiac tissue is necessary to salvage the myocardium; however, 
reperfusion also contributes to injury (17). The reoxygenation of myocardium 
results in significant generation of reactive oxygen species (ROS) which can 
trigger inflammation and damage proteins, lipids, and DNA, ultimately leading to 
cellular dysfunction and death. ROS generation within the myocardium also plays 
a protective role by generating growth factors that promote angiogenesis, 
promoting activation of vascular smooth muscle cells and matrix 
metalloproteinases (MMPs) that are necessary for the reparative phase (12). 
MMPs degrade intermyocyte collagen thereby expanding the infarct resulting in 
ventricular dilation leading to ventricular dysfunction (18). Overall, MI leads to a 
complex adaptive response, resulting in an attempt to salvage myocardium and 
preserve heart function. However, the end result of MI is cardiac dysfunction. 
Two prevailing details of MI induced cardiac dysfunction, cardiomyocyte cell 
death and ROS generation, share a common link: mitochondria.   
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Mitochondria   
History  
 Mitochondria arose from bacteria and developed a symbiotic relationship 
within cells (19). Mitochondria are membrane organelles contained within cells 
that carry out fundamental metabolism reactions necessary for cell survival. 
Mitochondria can also initiate apoptosis placing mitochondria at the interface 
between cell survival and cell death. The citric acid cycle (TCA cycle), beta-
oxidation of fatty acids and oxidative phosphorylation via the electron transport 
chain occur within mitochondria and these are essential metabolic pathways 
providing energy for the cell.   
 
Function 
Citric acid cycle  
  
 The TCA cycle was proposed by Hans Adolf Krebs in 1937 and is an 
oxidative pathway for the metabolism of carbohydrates, fats and amino acids. 
Eight enzymes comprise the TCA cycle that results in the oxidation of acetyl-
Coenzyme A (acetyl-CoA) resulting in production of three nicotinamide adenine 
dinucleotide reduced form (NADH), one flavin adenine nucleotide reduced form 
(FADH2), and one guanosine triphosphate (GTP) (20). The first reaction of the 
TCA cycle is the condensation of acetyl-CoA with oxaloacetate catalyzed by 
citrate synthase producing citrate. Citrate is then isomerized to isocitrate by 
aconitase and isocitrate is converted to alpha ketogluturate by isocitrate 
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dehydrogenase generating one NADH. Alpha ketoglutarate dehydrogenase then 
performs an oxidative decarboxylation reaction converting alpha ketoglutarate to 
succinyl-CoA, producing one NADH. Succinyl-CoA then undergoes a reaction 
with succinic thiokinase producing one GTP. Succinate dehydrogenase then 
converts succinate to fumarate producing FADH2 and this is followed by 
hydration of fumarate to malate by fumarase. The last reaction of the TCA cycle 
is the dehydrogenation of malate by malate dehydrogenase producing 
oxaloacetate, which can undergo condensation with another acetyl-CoA thereby 
starting another round of the TCA cycle. The NADH and FADH2 produced during 
the TCA cycle can donate electrons to the electron transport chain contributing to 
the production of adenosine triphosphate (ATP) via oxidative phosphorylation. An 
important source of acetyl-CoA for the TCA cycle is the beta oxidation of fatty 
acids.  
 
Beta Oxidation of Fatty Acids 
 
 Fatty acids enter into mitochondria via the carnitine palmitoyl carrier 
protein in which carnitine palmitoyl transferase I removes the CoA group on the 
fatty acid and attaches a carnitine moiety to a free fatty acid in the cytosol, which 
allows the fatty acid to pass through the carnitine carrier protein. Once inside the 
mitochondrial matrix, the carnitine moiety is removed by carnitine palmitoyl 
transferase II, and the CoA is reattached to the fatty acid. The beta oxidation of 
fatty acids occurs via four reactions catalyzed by acyl-CoA dehydrogenase, 
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enoyl-CoA hydratase, 3-L-hydroxyl-CoA dehydrogenase, and B-ketoacyl-CoA 
thiolase. Acyl-CoA dehydrogenase catalyzes dehydrogenation of the fatty acyl-
CoA creating a trans-alpha-beta double bond with the subsequent generation of 
FADH2, which enters the ETC via the electron-transfer flavoprotein (ETF) and the 
ETF:ubiquinone oxidoreductase. Enoyl-CoA hydratase then catalyzes the 
hydration of the trans-alpha-beta bond followed by NAD+ dependent 
dehydrogenation by 3-L-hydroxyl-CoA dehydrogenase generating NADH, which 
can enter into the ETC. B-ketoacyl-CoA thiolase cleaves the alpha and beta 
carbon to form acetyl-CoA, which can enter the TCA cycle, and a new acyl-fatty 
acid with two fewer carbon atoms, that can undergo another round of beta 
oxidation.  
 Mitochondria also contain additional enzymes for the oxidation of 
unsaturated fatty acids including: 1.enoyl-CoA isomerase, which re-positions a 
beta-gamma double bond into an alpha-beta position, 2. 2,4-dienoyl-CoA 
reductase and 3,2-enoyl-CoA isomerase, which catalyze the removal of a double 
bond at an even numbered carbon and 3.  3,5-2,4-dienoyl-CoA isomerase, which 
catalyzes a reversible reaction that interconverts trans-2 and trans-3 double 
bonds. Overall, one round of beta oxidation of fatty acids results in the production 
of acetyl-CoA, a substrate for the TCA cycle and one each of FADH2 and NADH, 
which can enter the ETC leading to the production of ATP.  
 




 The electron transport chain (ETC) is embedded in the inner mitochondrial 
membrane and is responsible for the majority of ATP production within the cell. 
The ETC is composed of 5 different protein complexes: NADH-coenzyme Q 
oxidoreductase (complex I), succinate-coenzyme Q oxidoreductase (complex II), 
coenzyme Q-cytochrome c oxidoreductase (complex III), cytochrome c oxidase 
(complex IV) and ATP synthase (complex V). Together complex I, II, III and IV 
transfer electrons to oxygen (O2), the final electron acceptor while also pumping 
hydrogen ions into the mitochondrial inner membrane space creating an 
electrochemical gradient. ATP synthase uses this electrochemical gradient for 
the phosphorylation of adenosine diphosphate (ADP) to ATP, thus the ETC 
couples electron transport to oxidative-phosphorylation for the production of ATP 
(Fig. 1).   
 
Complex I  
 Complex I, comprised of 46 subunits, is an L-shaped protein with one arm 
embedded in the inner mitochondrial membrane and the other arm extended into 
the mitochondrial matrix. Complex I transfers electrons from NADH to coenzyme 
ubiquinone (CoQ), a hydrophilic electron carrier within the mitochondrial inner 
membrane. Complex I contains a flavin mononucleotide (FMN) and nine iron 
sulfur clusters that participate in the transfer of electrons from NADH to CoQ via 
a mechanism according to the reduction potential of the various redox centers 
within complex I (21). FMN and CoQ can take up two oxidation states as both 
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Figure 1. Electron transport chain. The mitochondrial electron transport chain 
is composed of complex I, II, III, IV and ATP synthase. Electrons are carried 
down the chain to the final electron acceptor oxygen and protons are pumped by 






Figure 1. Electron transport chain.   
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form stable semiquinone radicals allowing both to donate either one or two 
electrons thus allowing NADH to transfer two electrons. In addition, to the 
transfer of electrons complex I also pumps 4 hydrogen ions into the inner 
membrane space contributing to the electrochemical gradient.  
 
Complex II  
 
 Complex II contains the TCA cycle enzyme succinate dehydrogenase and 
transfers electrons from succinate to CoQ. Complex II transfers electron from 
succinate to FAD initially followed by passage through three iron sulfur clusters, 
one cytochrome b560 and ultimately to CoQ. Complex II does not transverse the 
inner mitochondrial membrane or translocate hydrogen ions (22).  
 
Complex III  
  
 Complex III transfers electrons from reduced CoQ to cytochrome c while 
pumping 4 hydrogen ions into the inner membrane space, via the Q cycle (23). In 
the first step of the Q cycle, reduced CoQ binds to the Qo site where it transfers 
one electron to the iron-sulfur protein (ISP), containing the Rieske center, while 
releasing two protons into the inner membrane space. The ISP reduces 
cytochrome c1, while CoQ semiquinone transfers its remaining electron to 
cytochrome bL, a b-type cytochrome heme with low redox potential, yielding a 
fully oxidized CoQ (23). Cytochrome bL then reduces cytochrome bH, a b-type 
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cytochrome heme with high redox potential. The oxidized CoQ then is released 
from the Qo site and binds to the Qi site and receives an electron from 
cytochrome bH yielding CoQ semiquinone (24). This is the first cycle of the Q 
cycle, resulting in two hydrogen ions pumped into the inner membrane space, a 
reduced cytochrome c1 and a CoQ semiquinone. The second cycle of the Q 
cycle, is identical to the first cycle, however the CoQ semiquinone produced in 
the first cycle accepts an electron from cytochrome bH, along with two hydrogen 
ions from the mitochondrial matrix to produce a reduced CoQ (24). The electrons 
passed to cytochrome c1 are transferred to cytochrome c, a peripheral membrane 
protein that shuttles electrons from complex III to complex IV (24).  
 
Complex IV    
  
 Complex IV catalyzes one-electron oxidations of four cytochrome c 
molecules to reduce one oxygen molecule to two water (H2O) molecules. Four 
redox centers, cytochrome a, cytochrome a3, a copper atom known as CuB and a 
pair of copper atoms known as the CuA center participate in electron transfer of 
Complex IV (25). The transfer of electrons that occurs is linear from cytochrome 
c to CuA, to cytochrome a, then finally to cytochrome a3 and CuB. The 
cytochrome a3 and CuB are in close proximity to each other, almost forming a 
single binuclear complex, where the reduction of O2 to H2O occurs. The 
cytochrome a3 and CuB binuclear complex is reduced by two consecutive 
electron transfers from cytochrome c via cytochrome a and CuA, with the release 
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of H2O (25). Molecular oxygen binds to the heme of cytochrome a3 followed by 
internal electron redistribution in which tyrosine 244 of CuB has donated an 
electron and proton to the heme cytochrome a3, thereby forming a tyrosine 
radical, and this is known as the P compound (26). Electron transfer from 
cytochrome c along with two protons from the mitochondrial matrix allows 
tyrosine 244 to revert back to its phenolic state with the release of H2O. A final 
electron transfer from cytochrome c and acquisition of another proton yields an 
oxidized cytochrome a3-CuB complex completing the electron transfer cycle (26). 
Complex IV contributes to the electrochemical proton gradient by consuming four 
mitochondrial matrix hydrogen ions during the reduction of O2 to H2O thereby 
depleting matrix hydrogen ions and by translocating 4 hydrogen ions into the 
inner membrane space (26). The D channel extends from the mitochondrial 
matrix to the cytochrome a3-CuB center and connects with the exit channel. 
Together the D-channel and exit channel function to pump hydrogen ions from 
the matrix into the inner membrane space (25).   
 
ATP synthase  
  
 ATP synthase uses the electrochemical gradient created by complex I, III 
and IV to synthesize ATP from ADP and phosphate (Pi). ATP synthase is 
composed of two functional subunits, F0 and F1, where F0 is a transmembrane 
protein and F1 is a peripheral membrane protein (27). The F1 subunit is 
responsible for binding ADP, Pi and the formation of ATP and is composed of 
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three alpha and beta subunits along with a gamma, delta and epsilon subunit 
(27). The F0 subunit binds hydrogen ions and is composed of three 
transmembrane subunits, a, b and c (27). Hydrogen ions enter a hydrophilic 
channel between the a subunit and the c-ring where they bind to the c-subunit of 
the F1 subunit causing the c-subunit to rotate until it reaches another hydrophilic 
channel where it releases the hydrogen ion (28). The free energy released by 
hydrogen ion translocation drives the interconversion of the beta subunit of F0 
from a L (loose) state to a T (tight) state and an O (open) state (28). ADP and Pi 
bind to the beta subunit of F0 during the L state and the free energy provided by 
hydrogen ion transport causes conformational changes that covert the L state to 
a T state that catalyzes the formation of ATP (28). In addition, the other beta 
subunits are converted from a T state to an O state and from an O state to a L 
state, allowing ATP to dissociate from the O state (27).  
 Overall, the ETC of mitochondria provides energy to the cell in the form of 
ATP by coupling electron transport to oxidative phosphorylation by creating a 
proton gradient. Mitochondria are essential for cell survival by providing ATP. 
However, they also play a role in cell death via apoptosis.  
 
Mitochondrial mediated apoptosis 
  
 Intrinsic apoptosis is mediated by mitochondria following an apoptotic 
stimuli such as DNA damage or endoplasmic reticulum (ER) stress, which 
activate B cell lymphoma-2 (BCL-2) homology 3 (BH3)-only proteins, such as 
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BCL-2-associated X protein (BAX) (29) and BCL-2 antagonist or killer (BAK) (30). 
Upon activation BAX and BAK undergo oligomerization and target to 
mitochondria, where they induce mitochondrial outer membrane permeabilization 
(MOMP) (31). MOMP leads to the release of mitochondrial proteins such as 
cytochrome c, HtrA2 apoptosis inducing factor and SMAC (30). Cytochrome c 
binds to apoptotic-activating factor 1 (APAF1) leading to formation of the 
apoptosome, which recruits and activates caspase 9. Caspase 9 cleaves and 
activates caspase 3 and 7 leading to apoptosis. SMAC and HtrA2 serve to 
counteract the caspase inhibitory functions of X-linked inhibitor of apoptosis 
protein (XIAP) allowing for downstream activation of caspases and initiation of 
apoptosis (31). Regulation of mitochondrial mediated apoptosis during MI is 
essential in salvaging viable myocardium, thereby limiting cardiac injury (14).  
 
Role of Mitochondria in Myocardial Infarction  
 
 The activation of apoptosis by mitochondria during MI results in 
cardiomyocyte cell death and contributes to cardiac injury (14). Mitochondria also 
produce ROS during MI, damaging protein, lipids, and DNA leading to cardiac 
injury. Numerous studies have highlighted a role for mitochondrial dysfunction in 
CVD including increased mitochondrial DNA damage (32) and decreased 
mitochondrial respiration (33). Additionally, MI is associated with mitochondrial 
dysfunction including increased mitochondrial DNA damage (34), decreased 
mitochondrial encoded gene transcripts and decreased complex I, III, and IV 
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activity (34). Mitochondrial induced ROS generation is a hallmark of ischemic 
cardiac injury and believed to be the major contributor of cardiac injury. The 
electron transfer reactions within the ETC can result in the direct transfer of 
electrons to molecular O2 producing superoxide (O2
.-) (Fig. 2) that is dismutated 
to hydrogen peroxide (H2O2) by mitochondrial superoxide dismutase (MnSOD). 
Mitochondria therefore produce a basal amount of ROS during respiration. 
However, during MI there is an increase in ROS generation (18). The lack of 
oxygen during ischemic injury results in back up of electron flow through the ETC 
and reoxygenation following reperfusion results in a burst of ROS. Mitochondria 
contain several enzymes that can produce ROS, including 2-oxoglutarate 
dehydrogenase (35, 36) and pyruvate dehydrogenase (PDH) (37). However, 
complex I, II and III contribute the majority of ROS (38). Studies limiting ROS 
production by mitochondria during ischemic injury either by overexpression of 
antioxidants such as SOD (39) or direct modulation of complex I activity (40), 
provide cardiac protection highlighting the importance of regulating ROS 
production during ischemic injury. While mitochondria contribute to cardiac injury 
during MI via apoptosis and ROS generation; mitochondria can also provide 
protection against MI (17).   
 Ischemic preconditioning (IPC) was first demonstrated by Murry et al. in 
1986 in which short periods of ischemia could provide protection against a 
subsequent prolonged ischemic insult (41) and mitochondria play a prominent 
role in IPC. During IPC mitochondria can produce ROS that serve to activate 




Figure 2. Superoxide generated by mitochondria. Complex I, II, and III 
generate superoxide (O2
.-) during respiration due to electron slippage. During 
ischemia reperfusion conditions the rate of superoxide generated by complex I, II 

















Figure 2. Superoxide generated by mitochondria. 
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(Nrf2), hypoxia inducible factor 1 alpha (HIF-1α) (42), nuclear factor-kappa B (NF-
κB) (42), and adenine monophosphate kinase (AMPK) (43) that serve to protect 
myocardium against ischemic injury, highlighting a protective cell signaling role 
for mitochondrial ROS. Opening of the mitochondrial potassium-ATP (mitoKATP) 
channel and mitochondrial permeability transition pore (MPT) during IPC is also 
associated with cardioprotective effects (43). Alterations in mitochondrial 
respiration and ATP synthesis via mitochondrial uncoupling (44, 45), post-
translational modifications on mitochondrial proteins (complex I and adenine 
nucleotide translocase-1 (ANT-1)) (40, 46), and changes in mitochondrial 
membrane potential (47) are also associated with IPC cardiac protection.  Direct 
activation of these mitochondrial protective signaling pathways has also been 
shown to be cardioprotective against ischemic injury showing that mitochondria 
are critical mediators of cardioprotective signaling (42, 48).   
 
Role of Mitochondria in Aging   
 
 Aging is associated with a change in redox status of mitochondria. This 
change is related to an increase in ROS generation, where the antioxidant 
capacity within mitochondria becomes less efficient (42). Mitochondrial ROS 
generation is associated with mitochondrial DNA damage, mitochondrial protein 
damage and mitochondrial dysfunction in aging. Mitochondrial damage and 
dysfunction can trigger apoptosis leading to increased cell death during aging. 
Age is a significant risk factor for MI and is also associated with cardiac 
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dysfunction. ROS induced mitochondrial damage is seen both in aging and 
ischemic injury suggesting a similar mechanism of mitochondria induced cardiac 
dysfunction (42). Importantly, the mitochondrial protective signaling pathways 
against MI also serve to protect against aging induced mitochondrial dysfunction 




History and Sources  
 The anion nitrite (NO2
-) was considered an inert end product of NO 
oxidation and was used as an indirect measurement of nitric oxide synthase 
(NOS) activity. However, numerous studies have demonstrated that nitrite can 
serve as a signaling molecule and an endogenous reservoir of NO (49). The two 
main sources for NO2
- are the oxidation of NO and the reduction of dietary 
sources of nitrate (NO3
-), found in green leafy vegetables and meat, via 
commensal bacteria in the mouth. Initial data suggested the reduction of nitrite to 
NO under conditions of low pH and hypoxia was responsible for the resulting 
biological signaling actions (50). However, more recent data demonstrates that 
nitrite can mediate effects independent of its conversion to NO (40, 51).  
 
Nitric Oxide  
 Early studies of nitrite focused on its bioactivation to NO, as NO signaling 
has been shown necessary for normal cardiovascular health (52). Nitric oxide 
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was first discovered in the late 18th century and for 200 years was widely 
considered to be a toxic gas. In the 1980s, it was discovered that NO was 
generated in mammals by nitric oxide synthases (53). There are three forms of 
nitric oxide synthases (NOSs): the endothelial nitric oxide synthase (eNOS), the 
neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase 
(iNOS). NOSs are composed of homodimers (53). Each dimer contains a 
reductase and oxygenase domain that catalyzes a five electron transfer reaction 
and results in the conversion of L-arginine and molecular oxygen to L-citrulline 
with the concomitant production of NO (53). eNOS is found within the vascular 
endothelium, and the production of NO from eNOS is important for 
cardiovascular health, as NO maintains vascular tone and endothelial integrity 
(54). 
 NO can mediate biological signaling through three different pathways due 
to its free radical nature and high reactivity with transition metals and other free 
radicals. Direct interaction with ferrous heme proteins, direct diffusion-limited 
reactions with radicals, lipid peroxides and thiol radicals to form S-nitrosothiols 
and oxidative reactions with oxygen or ROS; represent the three distinct 
pathways in which NO can exert biological effects (55). Nitric oxide reactions 
occur with heme proteins and other radicals at low concentrations (picomolar to 
nanomolar) of NO due to the high affinity of NO for these compounds, while 
higher concentrations of NO and ROS are needed to form reactive nitrogen 




 Nitric oxide’s affinity for ferrous heme molecules leads to formation of an 
iron-nitrosyl complex and such binding activates soluble guanylate cyclase (sGC) 
(56). sGC activation leads to generation of the second messenger cyclic 
guanosine 3’-5’-monophosphate (cGMP), which activates protein kinase G (PKG) 
leading to relaxation of vascular smooth muscle and vasodilation within blood 
vessels (54). The NO-sGC-cGMP signaling cascade is the classical pathway by 
which NO facilitates regulation of vasomotor tone within the cardiovascular 
system (56). However, NO can also mediate a wide variety of effects including 
angiogenesis (56), mitochondrial biogenesis (56) and modulation of 
mitochondrial function (57). Conditions of increased oxidative stress, such as 
inflammation, MI, and aging, can impact NO signaling by decreasing NO 
availability and desensitizing sGC to NO (42). Increased O2
.- production during 
oxidative stress can react rapidly with NO to form peroxynitrite (ONOO-) thereby 
reducing NO concentrations (55).   
 Oxidative stress can also oxidize eNOS via glutathionylation (58) and 
reduce tetrahydrobiopterin (BH4) (58), a redox sensitive co-factor for eNOS. The 
loss of BH4 leads to uncoupling of eNOS, allowing electrons from NADPH to be 
passed to oxygen resulting in superoxide formation instead of NO (58). The 
ferrous heme of sGC can be oxidized to ferric heme resulting in sGC that is 
resistant to NO, thereby decreasing NO signaling (58). Loss of nitric oxide 
signaling and subsequent endothelial dysfunction is a hallmark of aging (42) and 
loss of nitric oxide in animals models of MI via NOS inhibition (52) or NOS 
genetic knockout (52) results in worsening cardiac injury. These studies highlight 
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a protective role of NO in aging and MI and the protection afforded by NO 
appears to be in part mediated by mitochondria.  
 Activation of the NO-sGC-cGMP pathway leads to opening of the mitoKATP 
channel leading to reduced calcium overload in mitochondria (59). Inhibition of 
MPT opening, thereby decreasing cytochrome c release and apoptosis (60) has 
also been attributed to nitric oxide. NO has also been shown to inhibit 
mitochondrial complex I (51), thereby decreasing ROS production and allowing 
diffusion of oxygen to ischemic tissue providing protection against ischemic 
injury. The hypoxic and acidic conditions associated with ischemic injury renders 
NOSs uncoupled leading to increased ROS and diminished NO production 
thereby limiting the therapeutic potential of NO against MI (52). However, nitrite 
represents an endogenous storage pool of NO (49).  
 
Nitrite Reduction 
 Nitrite can be reduced to nitric oxide under conditions of low pH, as was 
first noted by Furchgott (50) as acidified sodium nitrite solutions were able to 
mediate transient relaxation of rabbit aorta very similar to NO gas. Nitrite can be 
converted to NO in the acidic conditions such as the gastric lumen via non-
enzymatic reaction. Nitrite is protonated (HNO2) and decomposes to N2O3, giving 
rise to NO and NO2 (61). Nitrite can also be reduced to NO under hypoxic 
conditions by deoxygenated hemoglobin, where nitrite reacts with the ferrous 
hemoglobin and a proton to produce NO and methemoglobin (62). This reduction 
is highly dependent on low oxygen and low pH conditions, which arise during MI. 
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Nitrite reduction to NO can be catalyzed by several enzymes including: 
myoglobin (63), neuroglobin (64), cytochrome c (65), complex IV (66), eNOS (67) 
and xanthine oxidoreductase (68). While the exact mechanisms of nitrite 
reduction for all these enzymes is unknown, the prevailing conditions of low pH 
and hypoxia increase the reaction rate of nitrite reduction. The reduction of nitrite 
to NO, allows nitrite to mediate a variety of effects including: NO-sGC-cGMP 
signaling (69), metabolic signaling (70), vasodilation (62) and most importantly 
protection against ischemia reperfusion injury (40, 71-73).  
  
Nitrite and Myocardial Infarction 
 Nitrite was first shown to be cardioprotective in a Langendorff model of MI 
by decreasing infarct size (74). Abolishing NO signaling negates the protective 
effect of nitrite suggesting that reduction of nitrite to NO is required for 
cardioprotection as deletion of myoglobin, a nitrite reductase, in mice resulted in 
blunting of nitrite cardioprotection (75). This reinforces that nitrite reduction to NO 
is necessary for nitrite-mediated cardioprotection. Nitrite has also been shown to 
be protective in other models of ischemic injury including liver (76), brain (77), 
and hindlimb ischemia (78) with all of these studies indicating the reliance on 
nitrite reduction to NO. Nitrite also appears to be involved in the protection 
conferred by IPC as blood and tissue nitrite concentrations increase following 
IPC (79). Together these studies demonstrate that nitrite given during the acute 
phase of ischemia mediates protection against ischemic injury with mitochondria 




Nitrite and Mitochondria  
 Mitochondria contain several components that can serve to reduce nitrite 
to NO including complex III (80), complex IV (66), and cytochrome c (65). Nitrite 
can also serve to modulate mitochondrial function either directly via post-
translational modifications on complex I (40) and complex IV (81) or indirectly via 
mitochondrial biogenesis (82) and mitochondrial fusion (83, 84). Complex I 
induced ROS generation during the reperfusion phase of IR injury is a critical 
component of IR tissue injury and inhibition of complex I (85) has shown to be 
protective. Complex I activity has been shown to decrease with nitrite treatment 
during ischemia (73) and this decrease in complex I activity resulted in 
suppressed mitochondrial respiration ultimately leading to protection against IR 
injury (73) (Fig. 3).  
 A recent study by Chouchani et al. followed up on this nitrite-mediated 
decrease in complex I, and demonstrated that S-nitrosylation on cysteine 39 of 
the ND3 subunit was responsible for the decreased complex I activity (40). 
During ischemia when levels of NADH and oxygen are low, complex I activity is 
decreased and the ND3 subunit undergoes a conformational change exposing 
cysteine 39 (40). Nitrite and an exogenous NO donor given prior to ischemia are 
able to S-nitrosylate cysteine 39 and this modification decreases complex I 
activity, thereby attenuating ROS generated by complex I during reperfusion (40). 
Importantly, the S-nitrosylation on cysteine 39 is a transient, reversible 







Figure. 3. Mitochondrial targets of nitric oxide and nitrite. During normoxic 
conditions nitric oxide (NO) mediates cyclic GMP (cGMP) signaling and can 
inhibit complex IV, reducing oxygen consumption by mitochondria. Under low 
oxygen concentration nitrite (NO2
-) can be converted to NO by deoxygenated 
myoglobin (Mb), xanthine oxidoreductase (XO), complex III, and complex IV 
(ETC) allowing for complex IV inhibition. Nitrite can directly inhibit complex I via 
S-nitrosylation during ischemia resulting in suppressed oxidative stress leading to 
protection.  
Figure 3. Mitochondrial targets of nitric oxide and nitrite.  
Reprinted by permission from Macmillan Publishers Ltd: [Nature Chemical Biology] (Lundberg, J. O., M. T. Gladwin, A. 
Ahluwalia, N. Benjamin, N. S. Bryan, A. Butler, P. Cabrales, A. Fago, M. Feelisch, P. C. Ford, B. A. Freeman, M. 
Frenneaux, J. Friedman, M. Kelm, C. G. Kevil, D. B. Kim-Shapiro, A. V. Kozlov, J. R. Lancaster, Jr., D. J. Lefer, K. McColl, 
K. McCurry, R. P. Patel, J. Petersson, T. Rassaf, V. P. Reutov, G. B. Richter-Addo, A. Schechter, S. Shiva, K. Tsuchiya, 
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nutrition and therapeutics. Nature Chemical Biology 5: 865-869.) Copyright (2009)  
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ischemia. Overall, the S-nitrosylation on cysteine 39 within the ND3 subunit of 
complex I serves to decrease complex I generated ROS and preserve complex I 
activity.  
 Nitrite via conversion to NO has been shown to compete with oxygen for 
binding to the cytochrome a3 and CuB binuclear complex and this inhibits 
complex IV activity leading to suppression of oxygen consumption (81). NO 
inhibition of complex IV is reversible and this inhibition is thought to be a 
protective mechanism by preserving oxygen levels in hypoxic tissue.  
 Other mitochondrial mechanisms of protection with nitrite include inhibition 
of MPT opening (73), mitochondrial fusion (84), and AMPK activation (82). The 
opening of the MPT allows the release of cytochrome c into the cytosol inducing 
activation of the intrinsic pathway of apoptosis and nitrite is associated with 
decreased apoptosis in IR injury. The exact mechanism of nitrite reducing MPT 
opening and cytochrome c release remains unknown, as this may occur through 
reduction in ROS (40), direct inhibition of cytochrome c release via nitrosylation 
(86) or modulation of MPT protein components (87). Nitrite activation of PKA 
mediates phosphorylation of dynamin related protein 1 (Drp1) leading to 
inactivation and an increase in mitochondrial fusion (84). Attenuation of 
increased Drp1 protein levels following MI is associated with cardioprotection 
(88), suggesting that nitrite plays a role in mitochondrial dynamics. Nitrite induced 
mitochondrial fusion also leads to activation of AMPK leading to mitochondrial 
biogenesis (84) and AMPK activation is known to be cardioprotective (89). 
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Overall, mitochondria appear to play a prominent role in protective effects of 
nitrite.   
 The numerous studies highlighting the cardioprotective effects of nitrite 
lead to two clinical trials to determine whether nitrite supplementation during 
acute MI in humans was protective (90, 91). Both clinical trials cited no protective 
effect of nitrite in acute MI, suggesting that nitrite-mediated cardioprotection is 
not applicable in humans. While the hypoxic environment allows for nitrite 
conversion to NO, it also allows the formation of nitrogen species such as 
nitrogen dioxide and NO+. Additionally, NO can react with superoxide to form 
peroxynitrite. Nitrogen dioxide and peroxynitrite can react with thiols and 
tyrosines on proteins (92), altering protein function. Nitrogen dioxide and the 
nitrosonium ion can react with alkenes resulting in the formation of nitro-fatty 
acids (93). In this regard the cardioprotection afforded by nitrite may be 
influenced by the surrounding environment such as proteins or alkenes that can 
be post-translationally modified by secondary nitrogen species arising from 
nitrite.  
 
Conjugated Linoleic Acid  
 
Sources and Structure 
 Conjugated linoleic acid or cLA is an 18:2 unsaturated fatty acid and is an 









Figure 4. Cis-9 trans-11 isomer of conjugated linoleic acid. Conjugated 
linoleic acid is an 18:2 fatty acid with the cis-9 trans-11 isomer containing two 


















Figure 4. Cis-9 trans-11 isomer of conjugated linoleic acid  
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9 trans-11 and trans-10 cis-12 isomers comprising the majority of the cLA (94). 
cLA is produced in ruminant animals by two pathways: 1. bacteria within the 
stomach that isomerizes linoleic acid to cLA and 2. delta-9-desaturase 
conversion of vaccenic acid (trans-11 18:1 fatty acid) to cLA. The delta-9-
desaturase pathway of cLA represents the majority source of cLA in cattle (95). 
cLA is found within a variety of foods including beef, pork, lamb, chicken, milk, 
butter, cheese, and vegetable oils (96). The total amount of cLA in beef is 
approximately 1% of fat and cLA content can increase by supplementing forage 
and oils to cattle (97). The majority of total cLA within dietary food products is 
composed of the cis-9 trans-11 isomer of cLA representing approximately 90% of 
total cLA. The estimate of dietary intake of cLA within adults in the United States 
is 0.2g/day (98), with dietary habits such as higher intake of ruminant fat 
influencing individual dietary intake of cLA. cLA levels can also be increased by 
cLA supplementation, as cLA is commercially sold as a weight loss supplement 
that is unregulated by the Food and Drug Administration (FDA) (99). The FDA 
also excludes cLA from nutrition labeling regulations requiring levels of trans fats 
in food to be disclosed, as cLA is labeled as a natural trans-fat (99). As trans fats 
from hydrogenated oil are linked to increased cardiovascular risk factors, efforts 
have been made to understand the role of cLA in cardiovascular health and 
disease.  
 
Biological Role of cLA   
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 Conjugated linoleic acid has been evaluated in numerous epidemiological 
studies assessing the risk of cardiovascular disease or MI (100, 101). cLA 
displayed neither a positive nor a negative correlation for development of MI or 
cardiovascular disease, with exception of one study in which adipose cis-9 trans-
11 cLA was associated with lower risk of MI (102). cLA can act as a peroxisome 
proliferator-activated receptors (PPARs) agonist and PPAR activation leads to 
gene transcription involved in lipid metabolism, insulin signaling and inflammation 
(103). The effect of cLA on weight loss in animal models has translated over to 
humans as cLA is commercially sold as a weight loss supplement. However, the 
FDA does not regulate cLA. The target patient population for cLA 
supplementation is obese individuals setting to lose weight.  
 In clinical trials of obese individuals cLA had no effect on lipid profiles and 
the cis-9 trans-11 isomer of cLA increased 8-iso-prostaglandin F2α (8-iso-
PGF2α) levels in urine (104). 8-iso-PGF2α is a marker of lipid peroxidation 
suggesting that cLA increases lipid peroxidation in obese individuals. cLA has 
been shown to increase ROS production in macrophages (105) and promote 
oxidative stress in cardiac tissue of male Wistar rats (106), potentially explaining 
the increased 8-iso-PGF2α in obese individuals. The cis-9 trans-11 isomer of cLA 
has been shown to uncouple eNOS and increase NADPH oxidase 2 (Nox2) 
protein expression in endothelial cells and murine cardiac tissue (107). This 
uncoupling of eNOS and increased Nox2 expression could lead to an increase in 
oxidative stress. In contrast to these results, cLA has also been shown to be 
beneficial. Healthy male individuals given 3 doses of cis-9 trans-11 cLA displayed 
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a significantly reduced total cholesterol to high density lipoprotein cholesterol 
(TC:HDL-C) ratio (108). The most significant beneficial effect of cLA in relation to 
cardiovascular disease is the reduction in atherosclerosis and total cholesterol 
(109-111). The cis-9 trans-11 isomer of cLA decreased atherosclerotic lesions in 
the aorta (109), reduced total cholesterol (110) and cholesterol accumulation 
within the aorta (111).  
 Two potential pathways for cLA’s mechanism of action have been 
described: 1. activation of PPARs and 2. inhibition of cyclooxygenase (COX), 
which is responsible for production of prostaglandins and thromboxane 
necessary for inflammation and vascularization (94). The activation of PPARα by 
cLA (112) leads to gene transcription of several genes involved in beta oxidation 
and increased mitochondrial biogenesis (113). The activation of PPARα links the 
ability of cLA to modulate lipid metabolism but PPARα knockout mice displayed 
similar lipid metabolism as wild type mice supplied with cLA (114), suggesting 
cLA mediates changes in lipid metabolism independent of PPARα (114). 
 Mitochondria play a central role in lipid metabolism as beta oxidation of 
fatty acids occurs within mitochondria and cLA has been shown to mediate 
changes at the level of mitochondria. cLA has been shown to inhibit the beta 
oxidation of other fatty acids within the liver (115), increase activity of carnitine 
palmitoyltransferase I (CPTI) (116) and increase activity of the mitochondrial 
citrate carrier (116). These results suggest cLA is able to directly modulate 
mitochondrial function; however the impact of cLA on cardiac mitochondrial 
function is unknown. 
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 The literature on cLA suggests a wide array of biological effects including 
beneficial, detrimental or no effect (101). This can be explained by dose and 
duration of cLA administration. Most animal studies using cLA give super 
physiological doses of cLA and the duration of cLA ranges from days to weeks 
(101). The composition of the cLA dose is important to consider as well, and the 
majority of studies have used an isomeric mixture of cLA composed of both cis-9 
trans-11 and trans-10 cis-12. This is an important characteristic of study design 
as these isomers can have differing effects on study end points (101). Due to the 
high abundance of the cis-9 trans-11 isomer of cLA within the diet it is important 
to study the isomeric specific effects. The cis-9 trans-11 isomer of cLA decreased 
cardiac function in aged mice and co-administration of nitrite reversed this 
cardiac dysfunction (107). The interaction of cLA and nitrite brings up an 
overlooked mechanism of action of cLA; the nitration of cLA. Due to the 
conjugated double bond nature of cLA, the cis-9 trans-11 isomer is the preferred 
endogenous substrate of fatty acid nitration (117).  
 
Nitrated Fatty Acids  
 
Mechanisms of Formation  
 The formation of nitrated fatty acids is induced by NO derived species 
reacting via multiple mechanisms, ultimately resulting in the addition of nitrogen 
dioxide to a double bond. Peroxynitrite, oxidation of nitrite, protonation of nitrite, 
and aerobic reactions of NO (93) are all mechanisms that can mediate nitration 
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of fatty acids; thereby depicting a complex interaction between NO, NO derived 
oxides of nitrogen, peroxynitrite, and oxygen derived inflammatory mediators (ex. 
superoxide) leading to nitrated fatty acids. Fatty acids such as linoleic and oleic 
acid are targets of nitration due to their high abundance and double bond 
structure lending to nitrogen dioxide addition via either homolytic or hetrolytic 
reactions (93). The formation of nitrated fatty acids is influenced by 
microenvironment including:  aqueous vs hydrophobic environment, flux of 
nitrating and oxidizing species, antioxidants, and fatty acid beta-oxidation rates 
(118). Nitrated fatty acids exist in an equilibrium between the nitroalkene and 
nitrohydroxy form as nitro-fatty acids react under hydroxide anions within water 
(93). Nitroalkenes are stable in free or esterified forms under hydrophobic 
conditions such as lipid membranes or lipoproteins and once released to 
aqueous environments can either release NO, bind and activate PPARs, or post-
translational modify proteins (118).  
 
Biological Role of Nitrated Fatty Acids   
 Nitroalkenes decay in aqueous solutions leading to the release of NO; 
however, under physiologically conditions the release of NO by nitrated fatty 
acids is less than one percent (93). Nitroalkenes have been shown to activate 
PPAR gamma leading to decreased insulin and glucose levels in leptin deficient 
mice (119) and elevated nitrated fatty acids are found in the plasma of 
postprandial and hyperlipidemic humans (120). The activation of PPAR gamma 
by nitro-fatty acids was similar to the diabetic drug rosiglitazone without the 
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increased adipogenesis suggesting a unique mechanism of action of PPAR 
gamma by nitro-fatty acids (121). A more important and diverse role of nitrated 
fatty acids is in inflammation.  
 Due to the electrophilic nature of nitrated fatty acids, they can react with 
protein thiols and histidine residues, thereby modulating cell signaling (93). 
Kelch-like ECH-associating protein 1 (KEAP1) is a cytoplasmic repressor protein 
of Nrf2 which holds Nrf2 in the cytoplasm in an inactive state. KEAP1 contains a 
reactive cysteine that undergoes electrophilic modification by nitrated fatty acids 
(122) allowing Nrf2 to translocate to the nucleus and upregulate the transcription 
of phase II antioxidant enzymes. Heme-oxygenase-1 (HO-1) is one of these 
phase II antioxidant enzymes and nitrofatty acids have been shown to increase 
HO-1 protein expression (123). Nitrated fatty acids can also nitroalkylate p65, a 
component of the NF-κB inflammatory signaling pathway, thereby inhibiting p65 
DNA binding (124) and decreasing pro-inflammatory cytokine gene expression.   
 Due to the increase in nitrative and oxidative stress associated with MI, 
the formation of nitrated fatty acids increases following ischemia reperfusion 
injury (125). The exogenous administration of a nitrated oleic acid prior to 
ischemia reperfusion injury reduced infarct size (47), showing endogenous 
generation or exogenous administration of nitrated fatty acids is cardioprotective. 
Research into the mechanisms by which nitroalkenes mediate cardioprotection 
highlighted a mitochondrial mechanism as nitroalkenes promote mitochondrial 
uncoupling (47) and nitroalkylation of ANT-1 (46). Importantly, mitochondrial 
targeted nitroalkenes are more protective than non-mitochondrial nitroalkenes 
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(126). Recent evidence has shown that cLA is the preferred endogenous 
substrate for fatty acid nitration, generating nitro-cLA (117, 127) and a 
combination of cLA and nitrite is protective against cardiac injury (88). Due to the 
highly dependent role of mitochondria on nitro-fatty acid cardioprotection, it 
remains unknown if precursors to fatty acid nitration (cLA and nitrite) modulate 
mitochondrial function under baseline and cardiac injury settings.   
 
Hypothesis and Research Strategy  
 It is clear that cLA, nitrite and mitochondria play important roles in 
cardiovascular health and disease; therefore it is important to investigate the 
effect of cLA and nitrite consumption on mitochondrial function. To evaluate the 
impact of cLA and nitrite on cardiac mitochondrial function the following 
hypothesis was proposed: Co-treatment of cLA and nitrite protects against 
cardiac injury and age related cardiac dysfunction via beneficially altering 
mitochondrial function.  
 In this study, cardiac mitochondrial function was examined under baseline 
and cardiac injury conditions following cLA, nitrite and the combination treatment 
of cLA and nitrite. We first examined the impact on cardiac mitochondria 
following a ten day treatment with cLA, nitrite and co-treatment with cLA and 
nitrite under baseline conditions. This was followed up by examining the impact 
of MI and aging on cardiac mitochondrial function and how treatment with cLA, 
nitrite and co-treatment with cLA and nitrite mediated changes in cardiac 
mitochondrial function following MI and aging.  
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 Our results demonstrate that co-treatment with cLA and nitrite decreases 
mitochondrial state 3 respiration and complex III activity. In addition, we found 
that MI increases mitochondrial state 3 respiration, complex III activity, and 
hydrogen peroxide generation. However, the co-treatment of cLA and nitrite was 
able to attenuate these changes, potentially contributing to cardioprotection. 
These results reveal that in vivo supplementation of cLA and nitrite is able to 




















CHAPTER II  
MATERIAL AND METHODS 
 
Experimental Procedures  
Animals  
 C57BL/6J mice were obtained from Jackson Laboratory and all animal 
studies were approved by the University of Louisville Institutional Animal Care 
and Use Committee. Mice were fed standard chow and water ad libitum.  
 
Experimental Design  
 Chapter III  
  C57BL/6J mice divided into four groups: control, cLA, nitrite,  and 
cLA/ nitrite. cLA was given via osmotic mini-pump (20mg/kg/d) and sodium nitrite 
(50ppm) was supplemented in drinking water for 10 days.  
 Chapter IV  
  C57BL/6J mice were divided into eight groups: control, cLA, nitrite, 
cLA/nitrite, MI- control, MI- cLA, MI- nitrite, MI- cLA/nitrite. cLA was given via 
osmotic mini-pump (20mg/kg/d for non-MI and 10mg/kg/d for MI) and sodium 
nitrite (50ppm) was supplemented in drinking water for 3 days prior to MI and 
continued for 10 days after MI.   
 Chapter V  
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  C57BL/6J mice were aged to 10 or 33 month prior to treatment.  
Mice were divided into four groups: control, cLA, nitrite,  and cLA/ nitrite. cLA was 
given via osmotic mini-pump (20mg/kg/d) and sodium nitrite (50ppm) was 
supplemented in drinking water for 6 weeks.  
 
Blood Glucose Measurements  
 Mice were fasted overnight prior to blood glucose measurements from tail 
blood using the TRUEresult (NIPRO Diagnostics) blood glucose monitor. 
Measurements were taken prior and following treatment for control, cLA, nitrite 
and cLA/nitrite.  
 
Mouse Model of Myocardial Infarction  
 Male C57BL/6J mice, 10- to 12-wks old, were anesthetized with 
isoflurane, intubated and ventilated with CWE advanced ventilator (Webster,TX). 
Body temperature was maintained with an Indus Temperature feedback/surgical 
table and ECG system. Aseptic procedure was used for preparation of the 
surgical site through scrubbing with a 0.8% chlorhexidine solution. A left 
thoracotomy was performed via the fourth intercostal space and the lungs 
retracted to expose the heart. After opening the pericardium, the left anterior 
descending (LAD) coronary artery was ligated with an 8–0 silk suture near its 
origin between the pulmonary outflow tract and the edge of the atrium. Ligation 
was deemed successful when the anterior wall of the left ventricle (LV) became 
pale in color. The lungs were inflated by increasing positive end-expiratory 
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pressure, and the thoracotomy side was closed in layers. The lungs were re-
expanded, and the chest was closed. The animals were removed from the 
ventilator and allowed to recover on a heating pad. Mice were checked daily for 
signs of pain or distress and buprenorphine at 0.05mg/kg SQ is given before and 
every 12h for 48 hours.  
 
Heart Mitochondria Isolation  
 Hearts were excised and placed immediately in ice cold isolation media 1 
(250mM sucrose, 0.5mM Na2EDTA, and 10mM Tris, pH 7.4). Hearts were 
minced, washed 3 times and homogenized at 40 RPM using the GKH- 
Homogenizer (Glas-Col). Heart homogenate was centrifuged at 1000 x g for 3 
minutes at 4°C and supernatant was filtered through gauze sponge into a new 
tube followed by centrifugation at 10,000 x g for 10 minutes. The mitochondrial 
pellet was washed using isolation media 2 (250mM sucrose, 0.5mM Na2EDTA, 
10mM Tris, and 1g/L BSA, pH 7.4) and centrifuged at 10,000 x g for 10 minutes.  
The mitochondrial pellet was washed again with isolation media 2 and 
centrifuged at 10,000 x g for 10 minutes. Following centrifugation the 
mitochondrial pellet was dissolved in respiration media (0.5mM EGTA, 3mM 
MgCl2, 60mM K-lactobionate, 20mM taurine, 10mM KH2PO4, 20mM HEPES, 
110mM Sucrose, and 1g/L BSA). Heart mitochondria concentration was 
determined using the Bradford Protein Assay and was used immediately for 





 Mitochondria (0.025mg/ml) was added to closed Oxygraph-2k (Oroboros 
Instruments) chambers containing 2ml of respiration buffer (0.5mM EGTA, 3mM 
MgCl2, 60mM K-lactobionate, 20mM taurine, 10mM KH2PO4, 20mM HEPES, 
110mM Sucrose, and 1g/L BSA). LEAK (proton leak) respiration was measured 
following addition of 10mM glutamate and 2mM malate, followed by addition of 
1mM ADP for measurement of State 3 respiration. Cytochrome c (2.5μM) was 
added following induction of State 3 respiration as a control to ensure maximal 
respiration in State 3 and evaluate integrity of the outer mitochondrial membrane. 
Oligomycin A (2.5μM) was then added to induce State 4 respiration, followed by 
addition of 3.5μM carbonyl cyanide p-trifluoro-methoxyphenyl hydrazone (FCCP) 
to obtain maximum mitochondrial respiration in the non-coupled state of electron 
transfer system capacity. Upon depletion of oxygen 0.5μM antimycin A, a 
complex III inhibitor, was added to the chamber followed by re-oxygenation to 
measure residual oxygen consumption due to oxidative side reactions. Figure 5 
shows representative Oxygraph-2k graph following respiration protocol.  
 
Complex I Activity Assay  
 Complex I activity assay was adapted from previously described method 
(128) with slight modification. Briefly, mitochondria were diluted to concentration 
of 0.2 μg/μl and sonicated (QSonica) 4x for 5 seconds. 12μg of mitochondria was 
added to reaction mixture (25mM potassium phosphate pH 7.4, 80μM NADH, 
2mM KCN, 2μM antimycin A, 60μM decyclubiquinone, and 3 mg/mL BSA) in 1.5 
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mL cuvette (Starna Cells) and change in absorbance was read at 340nm for 4 
minutes using Synergy 2 (BioTek) spectrophotometer. Rotenone (4μM) was 
added to reaction mixture to determine rotenone insensitive complex I activity 
and subtracted from total activity to determine rotenone specific complex I 
activity.   
 
Complex II Activity Assay 
  Complex II activity assay was adapted from a previously described 
method (129) with slight modification. Briefly, 5μg mitochondria was added to 
reaction mixture (25mM potassium phosphate pH 7.4, 50μM decyclubiquinone, 
80μM 2,6-Dichlorophenolindophenol sodium salt hydrate, 20mM succinate, 
1mg/mL BSA and 300μM KCN) in1.5 mL cuvette (Starna Cells) and incubated for 
10 minutes. Decyclubiquinone (50μM) was added to start reaction and change in 
absorbance was monitored at 600nm for 4 minutes using Synergy 2 (BioTek) 
spectrophotometer. Malonate (10mM) was added to reaction mixture to 
determine malonate insensitive complex II activity and subtracted from total 
activity to determine malonate specific complex II activity.  
 
Complex III Activity Assay  
 Complex III activity assay was adapted from a previously described 
method (129) with slight modification. Briefly, 5μg mitochondria was added to 
reaction mixture (25mM potassium phosphate pH 7.4, 100μM decyclubiquinol, 
75μM cytochrome c, 500μM KCN, and 100μM Na2EDTA) in 1.5mL cuvette and 
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change in absorbance was read at 550nm for 4 minutes using Synergy 2 
(BioTek) spectrophotometer. Antimycin A (10 μg/mL) was added to reaction 
mixture to determine antimycin A insensitive activity and subtracted from total 
activity to determine antimycin A specific complex III activity.   
 
Complex IV Activity Assay  
 Complex IV activity assay was adapted from a previously described 
method (129) with slight modification. Briefly, 5μg mitochondria was added to 
reaction mixture (50mM potassium phosphate pH 7.4, and 30μM reduced 
cytochrome c) in 1.5 mL cuvette (Starna Cells) and change in absorbance was 
monitored at 550nm for 4 minutes using Synergy 2 (BioTek) spectrophotometer. 
KCN (300μM) was added to reaction mixture to determine KCN insensitive 
activity and subtracted from total activity to determine KCN specific complex IV 
activity.  
 
Western Blot Analysis  
 Heart tissue was snap frozen in liquid nitrogen and isolated mitochondria 
were stored at -80°C until needed. Heart tissue was homogenized and protein 
concentration determined using Bradford Protein Assay. Heart tissue or isolated 
mitochondria samples were then sonicated 2x for 5 seconds and subjected to 
SDS-PAGE method. MitoProfile® Total OXPHOS Rodent WB Antibody Cocktail 
(1.5μg/mL) was purchased from ABCAM for NADH dehydrogenase ubiquinone 1 
beta subcomplex 8 (NDUFB8), succinate dehydrogenase complex subunit B 
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(SDHB), ubiquinol-cytochrome c reductase core protein II (UQCRC2), 
mitochondrially encoded cytochrome c oxidase 1 (MTCO1) and ATP synthase 
subunit alpha (ATP5A).  
 
H2O2 Assay 
  25μg of heart tissue supernatant was incubated in phosphate buffered 
saline (PBS) pH 7.4, 49μM Amplex® UltraRed (Invitrogen), and 0.1U/mL 
horseradish peroxidase (Simga) for 30 minutes. Absorbance was measured at 
560nm and hydrogen peroxide concentration was calculated using hydrogen 
peroxide standard curve.  
 
Statistical Analysis  
 Data are presented as mean ± SEM. One way ANOVA with Bonferroni 
post hoc test, two way ANOVA with Bonferroni post hoc test or unpaired 
Student’s t-test were performed to determine significance using GraphPad Prism 












COMBINATION TREATMENT WITH cLA AND NITRITE IN VIVO CHANGES 
MITOCHONDRIAL FUNCTION  
Chapter Overview  
 Nitrite and cLA are dietary components found in green leafy vegetables 
and runimant meat respectively. cLA and nitrite are reported to have overall 
benefits on cardiovascular health and studies have shown that either nitrite or 
cLA can mediate changes in the activity of mitochondrial proteins and influence 
mitochondrial metabolism. However, it is not known how a combination of both 
cLA and nitrite impacts cardiac mitochondrial function. Cardiac mitochondria are 
essential for maintaining normal cardiac function and the impact of dietary cLA 
and nitrite on cardiac mitochondrial function may have a profound impact on 
overall cardiac health and function. In this study we examined how cLA, nitrite 
and a combination treatment of cLA and nitrite impacted cardiac mitochondrial 
function and individual electron transport chain activity. This study is the first to 
show that nitrite and cLA impact cardiac mitochondrial function in vivo.  
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Introduction   
 Conjugated linoleic acid (cLA) is an 18:2 unsaturated fatty acid and an 
isomer of linoleic acid. cLA is found within ruminant meat and dairy products with 
the majority of dietary cLA, approximately 72-94%, composed of the cis-9 trans-
11 isomer. The dietary intake of cLA within the United States is approximately 
0.2g/ day (98) and intake can increase as cLA is commercially sold as a weight 
loss supplement. cLA plays a role in lipid metabolism and glucose homeostasis 
(130) via activation of peroxisome proliferator activated receptor (PPAR) 
activation (131). cLA can also directly mediate effects on mitochondria via 
inhibition of fatty acid beta oxidation (115), increased activity of carnitine 
palmitoyltransferase I activity  (116) and mitochondrial citrate carrier protein 
(116). The role of the cis-9 trans-11 isomer of cLA on cardiac mitochondrial 
function is unknown at this time.  
 Nitrite (NO2
-) is a dietary constituent found within spinach and beet juice. 
Dietary nitrite represents an endogenous reservoir of nitric oxide (NO), as nitrite 
can be reduced to NO (62). NO plays an important role in cardiovascular health 
due to its role in regulating vascular tone (62) via activation of soluble guanylyl 
cyclase. More recent evidence suggests nitrite is cardioprotective via 
mitochondrial dependent mechanisms including inhibition of mitochondrial pore 
transition opening (73), mitochondrial fusion (84) and post-translational 
modifications on complex I (40). Nitrite has also been shown to mediate changes 
upstream of mitochondria including activation of protein kinase A (PKA) which 
phosphorylates and inactivates dynamin related protein 1 (Drp1) leading to 
45 
 
increased mitochondrial fusion (84). Nitrite also serves to activate adenine 
monophosphate kinase (AMPK), (82) a metabolic sensor involved in modulating 
metabolism. Due to the dietary nature of nitrite and its effects on mitochondria it 
is important to assess how nitrite influences cardiac mitochondrial function.    
 Recent evidence from our lab reported that cLA induced cardiac 
dysfunction in aged mice that was rescued with nitrite supplementation (107) and 
combination treatment of cLA and nitrite is protective in a murine model of 
myocardial infarction (MI) (88). Cardiac mitochondria play an essential role in 
cardiac function and this study investigates how cLA and nitrite affects cardiac 



















 To test the hypothesis that co-treatment of cLA and nitrite would impact 
mitochondrial function, mitochondrial respiration (as outlined in Fig. 5) was 
assessed in cardiac mitochondria isolated from C57BL/6J mice treated with cLA, 
nitrite and co-treatment. Weight measurements (Fig. 6A), demonstrated animals 
remained healthy with given does of cLA and nitrite. Blood glucose (Fig. 6B) was 
also monitored, as cLA (132) and nitrated fatty acids (93) can impact blood 
glucose homeostasis, and was unaltered following all treatment groups. 
Assessment of cardiac mitochondrial function demonstrated that state 3 
respiration was significantly decreased following cLA and co-treatment with cLA 
and nitrite (Fig. 7B), while LEAK respiration (Fig. 7A), state 4 respiration (Fig. 7C) 
and ETS respiration (Fig. 7D) remained unchanged. The decrease in state 3 
respiration was reflected in the respiratory control ratio (RCR) of cLA and co-
treated mice (Fig. 7E) as the RCR was significantly decreased.  
 To determine if changes in mitochondrial respiration were due to changes 
in electron transport chain enzymatic activity, complex I,II, III and IV enzymatic 
activity assays were performed. Nitrite and the co-treatment of cLA and nitrite 
increased complex I activity (Fig. 8A) compared to control, while the combination 
treatment of cLA and nitrite decreased complex II (Fig. 8B) and III (Fig. 8C) 
activity compared to control. Complex II activity was also decreased with cLA 
treatment alone (Fig. 8B). Complex IV activity (Fig. 8D) showed no change with 
any treatment group and the ten day treatment of cLA, nitrite and co-treatment 
















Figure 5. Mitochondrial Respiration Protocol. Simultaneous changes in 
oxygen concentration (black line, left y-axis) and oxygen flux per V (gray line, 
right y-axis) is monitored over time following substrate addition (G + M; glutamate 
and malate) where indicated. Mitochondrial LEAK (proton leak), State 3, State 4, 
ETS (electron transfer system) and ROX (residual oxygen consumption) 


























































Figure 6. Treatment with cLA, nitrite or in combination does not alter 
animal weight and blood glucose. Weight (A) and blood glucose (B) were 
monitored and remained unchanged following 10 day treatment with cLA, nitrite 
and co-treatment with cLA and nitrite. (*p<0.05, control before vs control after, 
Two way ANOVA, n=4 for all groups.) 
 
 
Figure 6. Treatment with cLA, nitrite or combination does not alter animal weight and blood 
glucose.   
















































































































































































Figure 7. State 3 respiration decreases following cLA treatment. Ten day 
cLA and cLA + nitrite treatment decreases State 3 respiration (B) and the RCR 
(E) in cardiac mitochondria compared to control, while LEAK respiration (A), 
State 4 respiration (C) and ETS respiration (D) remain unchanged (*p<0.05 
compared to control, One way ANOVA. n=4 for control, cLA, and nitrite, n=8 for 
cLA + nitrite).                             




Figure 8. Co-treatment with cLA and nitrite decreases complex II and III 
activity, while increasing complex I activity. Complex I (A): cLA + nitrite and 
nitrite increase complex I activity (*p<0.05 compared to control, #p<0.05 
compared to cLA and cLA + nitrite, One way ANOVA, n=8 for control and cLA + 
nitrite, n=7 for cLA and nitrite). Complex II (B): cLA + nitrite and cLA decrease 
complex II activity (*p<0.05 compared to control, #p<0.05 compared to nitrite, 
cLA + nitrite, One way ANOVA, n=4 for all groups). Complex III (C): cLA + nitrite 
decreases complex III activity (*p<0.05 compared to control, #p<0.05 compared 
to cLA and nitrite, unpaired student t-test, n=7 for control, n=6 for cLA and n=4 
for nitrite and cLA + nitrite). Complex IV (D): Complex IV activity remains 
unchanged in all treatment groups (n=4 for all groups). 
Figure 8. Co-treatment with cLA and nitrite decreases complex II and III activity, while 
increasing complex I activity. 




























































































































Figure 9. Mitochondrial respiratory chain protein subunit levels remain unchanged following 
cLA, nitrite or combination treatment with cLA and nitrite. 


































































































































































Figure 9. Mitochondrial respiratory chain protein subunit levels remain 
unchanged following cLA, nitrite or combination treatment with cLA and 
nitrite. Representative western blot of NDUFB8, SDHB, UQCRC2, MTCO1, and 
ATP5A (A) protein expression from cardiac tissue of control, cLA, nitrite, and cLA 
+ nitrite treated mice. Quantitated levels of NDUFB8 (B), SDHB (C), UQCRC2 
(D), MTCO1 (E) and ATP5A (F) protein expression remain unchanged following 






































 The ten day treatment with cLA decreases state 3 respiration (Fig. 7B) 
and RCR (Fig. 7E) without changes in LEAK (Fig. 7A), state 4 (Fig. 7C) or ETS 
respiration (Fig. 7D). cLA treatment did not alter mitochondrial respiratory chain 
subunit proteins (Fig. 9), suggesting the changes in mitochondrial respiration 
were not due to changes in mitochondrial complex protein levels. cLA has been 
shown to alter mitochondrial substrate transporter activities (115, 116), inhibit 
beta oxidation (115) and shift skeletal muscle metabolism from oxidative to 
glycolytic metabolism (133). These results suggest the decrease in state 3 
respiration by cLA is mediated by decreases in mitochondrial substrate 
transporter activities or adenine nucleotide transport.  
  As nitrite has been associated with cardiac protection (72) and this 
protection is in part mediated by mitochondria, the impact of nitrite on cardiac 
mitochondrial function was assessed. Following a 10 day treatment of nitrite, 
LEAK, state 4, state 3 and ETS respiration (Fig. 7) remained unchanged. Nitrite 
supplementation has been shown to increase uncoupled mitochondrial 
respiration (84), and the ETS respiration (Fig. 7D) following nitrite treatment was 
increased albeit not significantly compared to control. These results show that 
nitrite does not impact cardiac mitochondrial respiration under baseline 
conditions. Interestingly, nitrite significantly increased complex I activity (Fig. 8A), 
while complex II (Fig. 8B), III (Fig. 8C) and IV (Fig. 8D) activity remained 
unchanged following nitrite treatment. The change in complex I activity was not 
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mediated by increases in complex I protein as NDUFB8, a complex I protein 
subunit, protein levels did not change (Fig. 9).  
 Nitrite has been shown to decrease complex I activity (40, 73), contrasting 
the results seen following nitrite treatment (Fig. 8A). The differing results most 
likely are due to the nitrite treatment on isolated mitochondria (73), ten minute 
administration of an NO donor (40) and the decrease in complex I activity 
occurred following cardiac injury. Complex I is prone to S-nitrosylation on multiple 
subunits (134) which could alter activity suggesting nitrite plays a more dynamic 
role in regulating complex I activity. Overall, these results demonstrate that nitrite 
does not alter cardiac mitochondrial respiration under baseline conditions and 
may play a more prominent role in regulating complex I activity.   
 As cLA and nitrite are both dietary constituents studying how these dietary 
components impact cardiac mitochondria together is important. The cis-9 trans-
11 isomer of cLA is the preferential substrate for fatty acid nitration in vivo (117) 
and nitrite can give rise to secondary nitrogen species that mediate nitration of 
fatty acids.  
 The co-treatment with cLA and nitrite was able to decrease state 3 
respiration (Fig. 7B) and the RCR (Fig. 7E), without altering LEAK (Fig. 7A), state 
4 (Fig. 7C), or ETS (Fig. 7D) respiration. This result mimics the single treatment 
of cLA on respiratory parameters (Fig. 7), suggesting the decrease in state 3 
respiration with the combination treatment is mediated by a cLA-dependent 
mechanism such as decreased mitochondrial substrate transport (116) or 
adenine nucleotide transport.  
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 The co-treatment was able to increase complex I activity (Fig. 8A), while 
decreasing complex II (Fig. 8B) and III (Fig. 8C) activity. The increased complex I 
activity (Fig. 8A) and decreased complex II activity (Fig. 8B) seen with the 
combination treatment of cLA and nitrite can also be linked to a nitrite dependent 
mechanism for complex I and cLA dependent mechanism for complex II activity. 
The decrease in complex III activity is dependent on the co-administration of cLA 
and nitrite and this could rely on the formation of nitrated-cLA. The decreased 
complex III activity could also potential contribute to the decreased state 3 
respiration seen with the combination treatment as complex III is the funnel for all 
electron flow with the electron transport chain. This would lead to decreased 
electron flow and state 3 respiration. 
 Supplementation with cLA and nitrite in healthy humans leads to an 
increase in nitrated-cLA within the plasma (127) and nitration of cLA occurs 
within the mitochondria (117). Nitrated fatty acids can post-translationally modify 
protein thiols and alter activity (135) and the Rieske subunit of complex III 
contains a thiol that has been shown to be S-nitrosylated within mouse cardiac 
tissue (134). The unchanged mitochondrial respiratory protein subunits following 
the co-treatment with cLA and nitrite (Fig. 9) further suggests a post-translational 
modification mechanism for the reduction in complex III activity.  
 Overall, these results demonstrate that the dietary constituents’ cLA and 
nitrite can significantly alter cardiac mitochondrial respiratory and electron 
transport chain activity in vivo. Importantly, cLA and nitrite together can decrease 
complex III activity, highlighting a complex interaction that occurs following 
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CO-TREATMENT OF cLA AND NITRITE IN VIVO ATTENUATES CARDIAC 
MITOCHONDRIAL DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION 
Chapter Overview   
 Nitrated fatty acids, arising from ischemic cardiac tissue, are 
cardioprotective in murine models of ischemia reperfusion injury through 
mitochondrial dependent mechanisms. cLA is the preferred endogenous 
substrate for fatty acid nitration and previous studies have demonstrated that co-
treatment with cLA and nitrite preserves cardiac function following MI. In this 
study we examine whether the combination treatment of cLA and nitrite alters 
mitochondrial function after MI. We demonstrate that the co-treatment with cLA




 Myocardial infarction (MI) results from blockage of a coronary artery 
leading to insufficient blood supply to cardiac tissue, ultimately resulting in 
cardiomyocyte death (136) and cardiac dysfunction (137). Normal heart function 
relies on adenosine triphosphate (ATP) generation from mitochondria. 
Mitochondria produce ATP via the electron transport chain (ETC) to provide 
energy for the cell. The ETC shuttles electrons from NADH via NADH ubiquinone 
dehydrogenase (Complex I) or FADH2 via succinate dehydrogenase (Complex II) 
down the ETC, while pumping protons across the inner mitochondrial membrane 
creating an electrochemical gradient. ATP synthase (Complex V) uses free 
energy created by the electrochemical gradient to convert ADP to ATP, while 
cytochrome c oxidase (Complex IV) transfers electrons from cytochrome c to 
oxygen, the final electron acceptor (138). The coupling of electron transport and 
pumping of protons is essential for ATP synthesis. Mitochondria produce a basal 
rate of reactive oxygen species (ROS), contributed by complex I, II, and III, and 
MI results in increased ROS levels (34). The increase in ROS can result in lipid 
peroxidation (139) and decreased complex I, III and IV activity (34). Decreased 
ETC enzyme activity leads to decreased mitochondrial respiration following 
ischemia reperfusion injury (38), indicating that myocardial injury resulting from 
MI is associated with mitochondrial dysfunction.  
 Numerous studies have highlighted a role for mitochondria in 
cardioprotection including inhibition of mitochondrial permeability transition pore 
opening (140, 141), mild mitochondrial uncoupling (142), and mitochondrial 
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protein modifications (40, 143). Nitrated fatty acids have been shown to mediate 
cardioprotection in models of ischemia-reperfusion injury, via inhibition of p65 
(125) and directly at the mitochondrial level via protein modification of adenine 
nucleotide translocase-1 (ANT-1) (46).  
 9Z,11 E-octadecadienoic acid, also known as conjugated linoleic acid or 
cLA is an 18:2 fatty acid, which due to the nature of the conjugated double 
bonds, can undergo fatty acid nitration in the mitochondria (117). Recent 
evidence has shown that a combination treatment of cLA and nitrite is protective 
following myocardial infarction (88), overall demonstrating that precursors to fatty 
acid nitration mediate protective cell signaling.  Based on these findings, this 
study investigates how cLA and nitrite impact cardiac mitochondrial function in 
















 To test the hypothesis that co-treatment of cLA and nitrite would mediate 
cardioprotection via a mitochondrial mechanism; mitochondrial respiration was 
assessed (as outline in Fig. 5) in cardiac mitochondria from C57BL/6J mice 
treated with cLA, nitrite and co-treatment prior to and following MI. As treatment 
was given prior to MI, mitochondrial respiration was assessed following a 3 day 
treatment prior to MI and the combination treatment with cLA and nitrite had no 
impact on LEAK (Fig. 10A), state 3 (Fig. 10B) or ETS (Fig. 10C) respiration. The 
single treatment of cLA decreased LEAK respiration (Fig. 10A) with no change in 
other mitochondrial respiratory parameters (Fig. 10B-D). The single treatment of 
nitrite increased both state 3 (Fig. 10B) and ETS (Fig. 10C) respiration and this 
increase was reflected in the RCR (Fig. 10D).  
 Electron transport chain activities from complex I and III following 3 day 
co-treatment revealed that the combination treatment of cLA and nitrite 
significantly increased complex III activity (Fig. 11B), while complex I activity (Fig. 
11A) remained unchanged. Complex I and III activity were unaltered by the 
single treatments of cLA and nitrite (Fig. 11A-B). Complex III produces ROS 
(144), so to determine if the change in complex III activity increased ROS 
generation, hydrogen peroxide levels were measured in cardiac tissue following 
3 day co-treatment. Hydrogen peroxide levels were significantly increased 
following co-administration of cLA and nitrite and the single treatment of nitrite 
(Fig. 11C). Mitochondrial protein subunit expression was also examined following 
the 3 day combination treatment and the NDUFB8 protein subunit of complex I 
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was significantly decreased following co-treatment (Fig. 12A-B). All other 
mitochondrial protein subunits were unaffected for cLA, nitrite or the combination 
of cLA and nitrite (Fig. 12A-F).  
 Following MI, state 3 (Fig. 13B) and ETS (Fig. 13C) respiration 
significantly increased while LEAK respiration (Fig. 13A) and the RCR (Fig. 13D) 
remained unchanged. Supplementation with cLA was unable to alter MI induced 
changes in respiration (Fig. 13A-D). However, the single treatment of nitrite was 
able to attenuate MI-induced increases in state 3 (Fig. 13B) and ETS (Fig. 13C) 
respiration. Nitrite also increased the RCR (Fig. 13D) following MI. The 
combination treatment of cLA and nitrite was able to decrease state 3 (Fig. 13B) 
and ETS (Fig. 13C) respiration following MI with no change in LEAK respiration 
(Fig. 13A) or the RCR (Fig. 13D).  
 Electron transport chain activity was assessed to determine if changes in 
respiration were linked to alterations in complex I, II, III or IV activity. MI 
significantly increased complex I (Fig. 14A) and III (Fig. 14C) activity (Fig. 14A), 
while complex II activity was decreased (Fig. 14B). Complex IV activity (Fig. 14D) 
was unchanged following MI. cLA treatment further increased complex I activity 
(Fig. 14A), decreased complex II activity (Fig. 14B), and had no effect on 
complex III (Fig. 14C) or IV (Fig. 14D) activity following MI. Complex I activity 
(Fig. 14A) was increased further with nitrite treatment following MI, while complex 
III (Fig. 14C) and IV (Fig. 14D) activity remained unaltered with nitrite following 
MI; however, nitrite was able to restore complex II activity (Fig. 14B) to control 
levels following MI.  
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 The co-treatment with cLA and nitrite increases complex I activity following 
MI (Fig. 14A), had no effect on complex II activity (Fig. 14B), and was able to 
attenuate the MI-induced increase in complex III activity (Fig. 14C). Mitochondrial 
respiratory protein subunit expression revealed MI increased all respiratory 
subunit expression levels (Fig. 15A-F) and cLA, nitrite or co-treatment had no 
effect (Fig. 15). MI can cause increases in ROS production (34) and 
mitochondrial antioxidants play an important role in balancing ROS production. 
MnSOD protein expression was examined following MI and the co-treatment of 
cLA and nitrite significantly increased MnSOD protein expression after MI (Fig. 
16). Due to the combination treatment decreasing complex III activity and 
increasing MnSOD, hydrogen peroxide levels were assessed to determine if 
ROS production was changed following MI. Hydrogen peroxide levels are 
increased following MI (Fig. 17) and the single treatment of nitrite and co-
treatment with cLA and nitrite is able to attenuate the increased hydrogen 































































































































Figure 10. Mitochondrial respiraiton remains unchanged following co-
treament with cLA and nitrite. Three day cLA + nitrite treatment has no effect 
on LEAK (A, control n=8, cLA n=9, nitrite n=8, cLA + nitrite n=12), state 3 (B, 
control n=8, cLA n=7, nitrite n=7, cLA + nitrite n=11) or ETS (C, control n=8, cLA 
n=9, nitrite n=8, cLA + nitrite n=11) respiration. cLA decreases LEAK (A) 
respiration, while nitrite increases state 3 (B) respiration, ETS (C) respiration and 
the RCR (D, control n=8, cLA n=9, nitrite n=6, cLA + nitrite n=11). (*p<0.05 
compared to control, One way ANOVA). 
 
















































































Figure 11. Co-treatment with cLA and nitrite increases complex III activity 
and nitrite increases H2O2 levels.  Complex III activity (B) significantly 
increases following three day combination treatment and H2O2 levels significantly 
increases following nitrite treatment (C) while complex I actvitity (A) remains 









Figure 11. Co-treatment with cLA and nitrite increases complex III activity and nitrite 




Figure 12. Co-treatment with cLA and nitrite decreases NDUFB8 protein expression. 








































































































































































Figure 12. Co-treatment with cLA and nitrite decreases NDUFB8 protein 
expression. NDUFB8 protein expression (A-B) is significantly decreased 
following cLA + nitrite co-treatment. SDHB (A and C), UQCRC2 (A and D), 
MTCO1 (A and E), and ATP5A (A and F) protein levels remain unchanged 
following cLA, nitrite and co-treatment. (*p<0.05 vs control, One way ANOVA, 









































Figure 13. Nitrite attenuates increases in State 3 and ETS respiration 
following MI. MI increases state 3 (B, control n=8, MI n=6, MI - cLA n=7, MI - 
Nitrite n=5, MI - cLA + nitrite n=8) and ETS (C, control n=8, MI n=6, MI - cLA n=7, 
MI - Nitrite n=5, MI - cLA + nitrite n=8 ) respiration while LEAK respiration (A, 
control n=8, MI n=5, MI - cLA n=7, MI - Nitrite n=5, MI - cLA + nitrite n=8) and the 
RCR (D, control n=6, MI n=6, MI - cLA n=7, MI - Nitrite n=5, MI - cLA + nitrite 
n=8) remain unchanged. Supplementation with nitrite and cLA + nitrite decreases 
State 3 (B) and ETS (C) respiration following MI (*p<0.05 compared to control, 
#p<0.05 compared to MI, unpaired student t-test). 










































































































































































































Figure 14. Co-treatment with cLA and nitrite attenuates increased complex 
III activity following MI. MI increases complex I (A) and complex III (C) activity, 
decreases complex II (C) activity and has no effect on complex IV activity (D). 
cLA increases complex I (A) activity, decreases II (B) activity and has no effect 
on complex III (C) or IV (D) activity following MI. Nitrite increases complex I (A) 
activity, restores complex II (B) activity, and has no effect on complex III (C) or IV 
(D) activity following MI. Co-treatment with cLA + nitrite increases complex I (A) 
activity, decreases complex III (C) activity and has no effect on complex II (B) or 

































































































































































































































IV (D) activity following MI. Complex I: (control n=8, MI n=5, MI - cLA n=3, MI - 
Nitrite n=4, MI - cLA + nitrite n=6, *p<0.05 compared to control, #p<0.05 
compared to MI, $p<0.05 compared to MI - cLA, MI - cLA + nitrite, One way 
ANOVA). Complex II: (control n=4, MI n=6, MI - cLA n=3, MI - Nitrite n=5, MI - 
cLA + nitrite n=6, *p<0.05 compared to control, #p<0.05 compared to MI, MI- 
cLA, and MI- cLA + nitrite, $p<0.05 compared to MI, One way ANOVA). Complex 
III: (control n=7, MI n=6, MI - cLA n=3, MI - Nitrite n=5, MI - cLA + nitrite n=6, 
*p<0.05 compared to control, #p<0.05 compared to MI and MI- Nitrite, One way 
ANOVA). Complex IV: (control n=4, MI n=6, MI - cLA n=3, MI - Nitrite n=5, MI - 


























































Figure 15. Treatment with cLA, nitrite or combination increases mitochondrial 



























































































































































































































































































































Figure 15. Treatment with cLA, nitrite or combination increase 
mitochondrial respiratory protein expression following MI. Representative 
western blot of NDUFB8, SDHB, UQCRC2, MTCO1, and ATP5A (A) protein 
expression from isolated cardiac mitochondria from control, MI, MI - cLA, MI - 
Nitrite and MI - cLA + nitrite. MI- cLA increases SDHB (C), UQCRC2(D), MTCO1 
(E) and ATP5A (F) protein expression (*p<0.05 compared to control).  MI - Nitrite 
and MI - cLA + nitrite increases NDUFB8 (B), SDHB (C), UQCRC2 (D), MTCO1 
(E) and ATP5A (F) protein expression (*p<0.05 compared to control, #p<0.05 

































Figure 16. Treatment with cLA + nitrite increases MnSOD protein expression 
following MI. 
 
Figure 16. Treatment with cLA + nitrite increases MnSOD protein 
expression following MI. Representative western blots of MnSOD (A) protein 
expression from isolated cardiac mitochondria from control (n=4), MI (n=5), MI - 
cLA (n=4), MI - Nitrite (n=5) and MI - cLA + nitrite (n=6). Co-treatment with cLA 
and nitrite increases MnSOD protein expression following MI (B) (*p<0.05 
compared to control, unpaired student t-test). 
























































































Figure 17. Nitrite decreases H2O2 levels following MI. H2O2 levels increase 
following MI (n=4), MI - cLA (n=3) and MI - Nitrite (n=4) (*p<0.05 compared to 
control, n=4, One way ANOVA). However, supplementation with nitrite or cLA + 
nitrite (n=7) decreases H2O2  production following MI (#p<0.05 compared to MI 


























































Discussion   
 Recent evidence has shown that co-treatment with cLA and nitrite 
mediates protection against MI (88). cLA undergoes nitration in vivo (117) and 
nitrated fatty acids mediate protection against ischemic injury by mitochondrial 
dependent mechanisms (47, 126). Cardiac mitochondrial respiration and 
respiratory complex activity was assessed prior to and following MI with co-
treatment of cLA and nitrite to determine whether mitochondria played a role in 
this protection.  The major findings from this study reveal that co-treatment with 
cLA and nitrite is able to attenuate MI-induced increases in state 3 respiraiton 
(Fig. 13 B), ETS respiration (Fig. 13C), complex III activity (Fig. 14C) and 
hydrogen peroxide levels (Fig. 17), while increasing MnSOD protein expression 
following MI (Fig. 16).   
 The combination treatment was administered 3 days prior to MI and 
mitochondrial respiration was performed following 3 day treatment to determine 
mitochondrial changes ocurring prior to MI. The combination treatment of cLA 
and nitrite did not alter mitochondrial respiration parameters including: LEAK 
respiration (Fig. 10A), state 3 respiration (Fig. 10B), ETS respiration (Fig. 10C) 
and the RCR (Fig. 10D). These results indicate that mitochondrial respiration is 
functional with the co-treatment prior to MI.   
 The co-treatment prior to MI was able to significantly increase complex III 
activity (Fig. 11B) without changing complex I activity (Fig. 11A). The 
combination treatment did decrease NDUFB8 protein expression (Fig. 12A and 
B) without changing SDHB, UQCRC2, MTCO1 and ATP5A protein levels (Fig. 12 
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A-F). The NDUFB8 is not involved in the catalytic activity of complex I, thereby 
potentially explaining the unaltered complex I activity seen with the combination 
treatment despite decreased NDUFB8 protein levels.  
  As complex I and III can produce ROS (38), hydrogen peroxide levels 
were measured to determine if the increase in complex III activity correlated with 
an increase in ROS. Hydrogen peroxide levels were increased with both nitrite 
and the combination of cLA and nitrite (Fig. 11) indicating nitrite is increasing 
hydrogen peroxide levels independent of changes in complex III activity. 
However, the hydrogen peroxide was measured in cardiac tissue homogenate 
thereby the source of hydrogen peroxide could differ between the nitrite 
treatment and co-treatment as nitrite can increase NADH oxidase 2 (NOX2), a 
mediator of non-mitochondrial ROS generation (107).  
 Following MI, state 3 respiration (Fig. 13B) and ETS respiration (Fig. 13C) 
increased without changing LEAK respiration (Fig. 13A)  or the RCR (Fig. 13D). 
The increases in respiration following MI are in contrast to reports in the literature 
in which MI is associated with mitochondrial dysfunction (34). The differences 
observed in this study may be related to the time point, as mitochondrial 
respiration was assessed ten days after MI and most studies evaluate 
mitochondrial function within a short time period. Additionally, this time period 
allows for adaptive cell signalling to compensate for mitochondrial dysfunction 
and the increased mitochondrial respiratory protein levels following MI (Fig. 15A-
F) indicates an upregulation in electron transport chain protein expression to 
compensate for mitochondrial dysfunction.  
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 The single treatment of cLA was unable to alter changes in mitochondrial 
respiration induced by MI. However, single treatment of nitrite and combination 
treatment of cLA and nitrite was able to attenuate increased state 3 respiration 
(Fig. 13B) and ETS respiration (Fig. 13C) following MI. The reliance on nitrite to 
reduce mitochondrial respiration following MI in the single and combination 
treatment could be attributed to nitrite’s conversion to nitric oxide. Nitrite can 
undergo reduction to nitric oxide under conditions of hypoxia by deoxygenated 
hemoglobin (62), deoxygenated myoglobin (63), and low pH (145), all conditions 
that prevail following MI. Nitric oxide can inhibit mitochondrial respiration (81) 
demonstrating that the nitrite mediated decreases in respiration observed 
following MI could be linked to nitrite’s conversion to nitric oxide.  
 MI increased complex I activity (Fig. 14A) and cLA, nitrite and the 
combination treatment further increased complex I activity (Fig. 14A). The 
increased complex I activity following MI is contrary to literature in which cardiac 
injury decreases complex I activity (34). The observed differences in this study 
could be due to the time point in which complex I activity was assessed (10 days) 
or the area of cardiac tissue from which mitochondria were isolated (border zone 
vs whole heart). Both the cLA and co-treatment of cLA and nitrite are significantly 
higher than the MI and MI – Nitrite group indicating cLA is the mediator of this 
increase. cLA has been shown to increase ROS in macrophages (105), oxidative 
stress in rat cardiac tissue (106), and 8-iso-prostaglandin F2α urine levels in 
obese males (104). cLA has also been shown to induce cardiac dysfunction in 
aging by uncoupled eNOS (107). These results suggest that cLA may exacerbate 
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oxidative stress conditions such as MI, aging and obesity. The increased 
complex I activity observed with cLA following MI may provide a mechanistic link 
between cLA and the detrimental effects observed with cLA in oxidative stress 
conditions.  
 Complex II activity was significantly decreased following MI (Fig. 14B) and 
neither cLA nor the co-treatment was able to restore complex II activity after MI 
(Fig. 14B). Nitrite administration restored complex II activity following MI (Fig. 
14B); however, the restoration of complex II activity is not necessary to mediate 
cardioprotection as nitrite was unable to provide protection against MI (88). 
 MI significantly increased complex III activity (Fig. 14C) and the single 
treatments of cLA and nitrite were unable to decrease MI induced upregulation of 
complex III activity. The increased complex III activity following MI differs from 
literature reports in which cardiac injury decreases complex III activity (34) and 
this is most likely due to the border zone of the infarct being used for cardiac 
mitochondrial complex III activity as opposed to whole heart.  
 The combination of cLA and nitrite was able to attenuate the increased 
complex III activity following MI (Fig. 14C). The decreased complex III activity 
mediated by cLA and nitrite could rely on the formation of nitrated cLA since cLA 
undergoes nitration within mitochondria (117) and formation of nitrated fatty acids 
increases following ischemic injury (125). The Reiske subunit of complex III 
contains a thiol that can be S-nitrosylated (134) and the alkanine conditions 
within mitochondria promote nitro-fatty acids to react with thiols (135). These 
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conditions favor a mechanism by which nitrated cLA is able to post-translationally 
modify complex III, thereby decreasing its activity following MI.  
 High levels of ROS generated by complex I and III during MI can result in 
cardiac damage and upregulated complex I and III activity following MI correlated 
with increases in hydrogen peroxide after MI (Fig. 17). Supplementation with 
nitrite and the combination of cLA and nitrite was able to attenuate the increased 
hydrogen peroxide levels (Fig. 17), while the single treatment of cLA was unable 
to decrease the levels (Fig. 17). The decreased complex III activity following co-
treatment of cLA and nitrite could explain the decreased hydrogen peroxide 
levels generated after MI; however the single treatment of nitrite also decreased 
the hydrogen peroxide levels. An alternative explanation could be attributed to 
nitrite derived NO reaction with superoxide thereby reducing the pool of 
superoxide that can be converted to hydrogen peroxide.  
 Overall, these results suggest the cardiac protection afforded by the 
combination treatment of cLA and nitrite may be in part mediated by attenuation 













CARDIAC MITOCHONDRIAL FUNCTION AND AGING  
Chapter Overview  
 Aging and ischemic injury share similarities of cardiac mitochondrial 
dysfunction resulting in decreased heart function. cLA and nitrite are found within 
dietary foods such as runimant meat and green leafy vegetables. Nitrite and cLA 
have both been associated with cardiovascular health and appear to mediate 
these effects through mitochondria. However, the impact of nitrite and cLA on 
cardiac mitochondria in aging is unknown. Recent evidence has shown that cLA 
supplementation in aged mice decreased cardiac function and supplementation 
of nitrite was able rescue this dysfunction. This study examines the impact of 
aging on cardiac mitochondrial function and examines whether co-treatment with 
cLA and nitrite rescues cardiac mitochondrial dysfunction. This study reveals 
there is an age dependent decline in cardiac mitochondrial function and 
supplementation with the combination treatment of cLA and nitrite was unable to 




 Aging is associated with cellular changes ultimately resulting in declines in 
cellular function (146). The development of cardiovascular disease and risk for 
MI increases with age (146). Aging is associated with increased oxidative stress 
(147) and mitochondrial driven ROS contributes to this elevated oxidative stress 
condition. Aging results in diminshed mitochondrial function (148-150) thereby 
limiting the ATP pool needed to maintain normal cardiovascular function. 
Mitochondria also play an important role in mediating cardioprotective effects 
against MI (32); however, these protective effects are lost in aging (42). One of 
the theories behind this loss of cardioprotection is loss of mitochondrial function  
(42), so strategies to improve mitochondrial function in aging could restore 
mitochondrial mediated protection against MI. Nitrite and cLA are dietary 
consitutents that are known to influence mitochondrial function (73, 115) and 
mediate cardioprotection (88). However, it is unknown if these effects carry over 
to aged mitochondria. This study was undertaken to determine whether cLA, 
















 Mitochondrial respiration assessed in 10 and 33 month old revealed an 
aged dependent decline in mitochondrial respiratory capacity. Ten-month old 
mice displayed a significant decrease in state 3 respiration (Fig. 18B) with a 
concurrent decrease in the RCR (Fig. 18D). LEAK respiration (Fig. 18A) was not 
decreased in 10 month old mice. The ETS respiration (Fig. 18C) appeared to be 
decreased, though it was not statistically significant. When mice were aged to 33 
months, there was a significant decline in both LEAK (Fig. 18A) and state 3 (Fig. 
18B) respiration compared to 8-12 week old mice. The ETS respiration was 
noticeable decreased in 33 month old mice (Fig. 18C), but was not statistically 
significant. The RCR (Fig. 18D) was not changed. To assess whether 
supplementation with cLA and nitrite could rescue aged related declines in 
mitochondrial function, 10 month old mice were treated with cLA, nitrite or the 
combination treatment of cLA and nitrite for 6 weeks after which mitochondrial 
function was assessed. Treatment with cLA, nitrite or co-treatment did not alter 












Figure 18. Aging induces cardiac mitochondrial dysfunction. 10 month old 
mice have reduced state 3 (B) respiration, ETS respiration (C) and RCR (D), 
while LEAK respiration (A) remained unchanged. LEAK (A), state 3 (B) and ETS 
(C) respiration was decreased in 33 month old mice, while the RCR (D) remained 
unchanged. (*p<0.05 vs 3 month, unpaired student t-test, 3 month n=4, 10 and 








Figure 18. Aging induces cardiac mitochondrial dysfunction.  











































































































































































































































































































































































Figure 19. Treatment with cLA, nitrite or in combination does not attenuate 
aged related decline in cardiac mitochondrial function. Six week treatment 
with cLA, nitrite and cLA + nitrite was unable to rescue reduced state 3 
respiration (B), ETS respiration (C) or the RCR (D). LEAK (A) respiration was 
unchanged following treatment with cLA, nitrite or cLA + nitrite. (*p<0.05 vs 
Figure 19. Treatment with cLA, nitrite, or in combination does not attenuate aged related 
decline in cardiac mitochondrial function.  
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control, One way ANOVA, control n=4, control - 10 month, cLA - 10 month, Nitrite 















































Discussion   
 Age is a significant risk factor for cardiovascular disease and subsequent 
complications such as MI (151). The development of cardiovasuclar disease in 
aging is associated with mitochondrial dysfunction and increased oxidative stress 
(147). Mitochondrial generated ATP is essential for maintaining normal 
cardiovascular health and plays a protective role against MI (32). However, with 
aging, the protective role of mitochondria against MI is lost (42) and this is 
thought to be associated with a decline in mitochondrial function. As 
demonstrated in this study, mice aged to 10 or 33 months displayed decreased 
mitochondrial function (Fig. 18). The 33 month-old mice had significantly 
decreased LEAK (Fig. 18A) and state 3 (Fig. 18B) respiration, while the 10 
month-old mice only had a decrease in state 3 respiration (Fig. 18B).  
 The decrease in state 3 respiration but not LEAK respiration for the 10 
month-old mice suggests that under low energy demand the ETS is able to 
effectively transport electrons down the ETS. However, under high energy 
demands requiring production of ATP, the ETS is unable to meet these 
demands, resulting in supressed state 3 respiration. As aging continues, the ETS 
further declines in electron transporting capacity, resulting in the diminished 
LEAK and state 3 respiration observed in the 33 month-old mice. This can result 
in over production of mitochondrial generated ROS (152) coupled with reduced 
antioxidant defenses (153), ultimately resulting in damage to the oxidative 
phosphorylation proteins within the ETS and leading to mitochondrial 
dysfunction. The ETS was reduced in both 10 and 33 month old-mice; however, 
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it was not statistically significant. This is likely due to the low number of mice per 
group and over titration of the mitochondrial uncoupler resulting in greater 
variability within the ETS respiration. Overall, these data shows there is an age 
dependent decline in mitochondrial function.  
 Nitrite is considered an endogenous reservoir of NO that can be obtained 
from the diet by consuming green leafy vegetables or beet juice. Nitrite has been 
shown to increase mitochondrial function in adipocytes (83) and modulate 
cardiac mitochondrial function under injury settings (51); however the effect of 
nitrite on aged cardiac mitochondrial function is unknown. This study assessed 
whether nitrite supplementation could rescue aged related cardiac mitochondrial 
dysfunction and found that it could not (Fig. 19). These results suggest that nitrite 
is unable to upregulate mitochondrial function either directly at the level of 
mitochondria or upstream such as upregulated activation of AMPK (83). 
Interestingly, nitrite supplemenation in aged mice treated with cLA was able to 
rescue cardiac left ventricular dysfunction (107). This was mediated by restoring 
eNOS dimerization and NO signaling. These results coupled with nitrite being 
unable to rescue aged mitochondrial function, suggest the more prominent role of 
nitrite in aging is to restore NO signaling which is lost within the vasculature 
during aging (107, 147).  
 cLA supplementation in aged mice resulted in worsening left ventricular 
cardiac function (107) and decreased mitochondrial function with cLA could 
explain this observation. Mitochondrial function from aged mice treated with cLA 
did not result in decreased mitochondrial function (Fig. 19A-D). Therefore, the 
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detrimental effects seen with cLA in aged mice is not due to diminishing cardiac 
mitochondrial function.  
 The increased oxidative and nitrative stress conditions associated with 
aging (147) favor the formation of nitrated fatty acids (93) and nitrated fatty acids 
(46, 125) along with precursors to fatty acid nitration (cLA and nitrite) are 
cardioprotective. Supplementation of cLA and nitrite in aged mice was unable to 
reverse the aged dependent decline in mitochondrial function (Fig. 14). These 
results suggest that a potential protective role of nitrated fatty acid or precursors 
to fatty acid nitration is not mediated through restoration of mitochondrial 
function. cLA and nitrite can upregulate HO-1 gene expression (88, 117) 
representing an alternative pathway for cardiac protection in aging.   
 Overall, these results demonstrate that cardiac mitochondrial function 
declines with age and supplementation with cLA, nitrite, or co-treatment is unable 












CHAPTER VI  
FUTURE DIRECTIONS AND CONCLUSIONS   
Conclusion  
  Cardiovascular disease is the leading cause of mortality within the United 
States with MI contributing the majority of morbidity. Clinical intervention to 
lessen cardiac injury following MI is limited, highlighting a need for further 
research and development of new therapeutic approaches. Conjugated linoleic 
acid and nitrite represent dietary constituents that may be utilized to lessen 
cardiac injury as the combination of these dietary substances preserves cardiac 
function in a murine model of MI. Due to the essential role of mitochondria in 
maintaining normal cardiac function and recent evidence detailing a 
mitochondrial mechanism for nitrated fatty acids, this study was undertaken to 
determine how precursors to fatty acid nitration (cLA and nitrite) impacted cardiac 
mitochondrial function. The first part of this study revealed that a ten-day 
combination treatment of cLA and nitrite decreases state 3 and ETS respiration, 
along with complex II and III activity. The combination treatment also increased 
complex I activity. These results reveal that in combination, cLA and nitrite can 
impact cardiac mitochondrial function in vivo.   
 Next, cardiac mitochondrial function was assessed under  two conditions 
of injury or stress, MI and aging. We then assayed whether co-treatment with 
cLA and nitrite was able to rescue mitochondrial dysfunction during these 
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conditions. In the setting of MI, the co-treatment was able to attenuate MI 
induced increases in state 3 respiration, complex III activity and hydrogen 
peroxide levels. These results reveal a potential mitochondrial mechanism for the 
cardioprotection mediated by co-treatment with cLA and nitrite. Cardiac 
mitochondrial function was suppressed following aging and the combination 
treatment with cLA and nitrite was unable to restore cardiac mitochondrial 
function. These results reveal that the mitochondrial effects mediated by cLA and 
nitrite are lost in a murine model of aging. Taken together, this study 
demonstrates that a combination treatment of cLA and nitrite is able to modulate 
cardiac mitochondrial function in vivo and reverse MI, but not aging- induced 
mitochondrial dysfunction.  
 
Future Directions  
cLA  
 This study revealed that cLA was able to repress cardiac mitochondrial 
function and decrease complex II activity in vivo. These results suggest cLA 
could potentially be able to alter mitochondrial metabolism. However, the 
mechanism leading to this outcome is unknown. Due to the numerous upstream 
cellular signaling linked to cLA (101) that can impact mitochondrial function, it is 
necessary to delineate whether cLA is functioning upstream of mitochondria or 
directly at the level of mitochondria. Incubation of isolated cardiac mitochondria 
with cLA followed by mitochondrial respiration will reveal if cLA mediates 
decreases in mitochondrial respiration directly at the level of mitochondria. Co-
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incubation of cLA with etomoxir (154), an inhibitor of fatty acid beta-oxidation, on 
isolated cardiac mitochondria will reveal whether full length cLA or a downstream 
oxidation product is necessary to mediate cLA effects on mitochondria. Transport 
of glutamate, malate, and ADP into mitochondria is necessary for mitochondrial 
respiration as the isolation of mitochondria depletes endogenous substrates. The 
cLA mediated decrease in state 3 respiration following cLA treatment suggests 
transport of ADP into in mitochondria is limited. ANT-1 is responsible for the 
transfer of ADP into the mitochondria and ATP out of mitochondria (155). The 
measurement of ANT-1 activity in isolated cardiac mitochondria from mice 
treated with cLA will be carried out using a magnesium sensitive dye, Magnesium 
Green. This will indicate if ANT-1 activity is decreased following cLA treatment 
and provide a potential mechanism by which cLA decreases mitochondrial 
respiration.  
 The mechanism for the cLA mediated decrease in complex II activity will 
be examined by assessing the activity of malate dehydrogenase. Malate 
dehydrogenase converts malate to oxaloacetate, which is a potent inhibitor of 
complex II activity. The cis-9 trans-11 isomer of cLA has been shown to increase 
malate dehydrogenase activity in the liver of rats (156) and high levels of 
oxaloacetate following cLA treatment may lead to decreased complex II activity.  
 
Nitrite  
 This study revealed that nitrite was able to increase complex I activity in 
vivo under baseline conditions. Complex I has been shown to undergo S-
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nitrosylation by an NO donor on cysteine 39 within the ND3 subunit under 
conditions of ischemic injury (40). This S-nitrosylation was able to transiently 
inhibit complex I activity and removal of this modification restored complex I 
activity (40). Interestingly, this modification is not seen under normoxic conditions 
with the NO donor. However, S-nitrosylation of cysteine 344 within the 75 kDa 
subunit is found under normoxic conditions (40). Mass spectrometry analysis 
examing S-nitrosylation of cysteine 344 within the 75 kDa subunit of complex I 
following nitrite treatment would correlate increased complex I activity with an 
increase in this modification; providing a link between nitrite treatment and 
increased complex I activity.  
 
Co-treatment of cLA and nitrite  
 The major findings of this study reveal that the combination treatment of 
cLA and nitrite was able to decrease complex III activity under baseline 
conditions and attenuate MI induced increases in complex III activity. Nitrated 
fatty acids can form adducts with free thiols via Micheal addition thereby altering 
protein activity (135). The cytochrome b-c1 complex subunit I, II and Rieske 
subunit all contain cysteiene residues that can be S-nitrosylated (134) and these 
residues may also undergo Micheal addition with nitrated fatty acids. Mass 
spectrometry analysis for nitrated cLA adducts to cysteine 69 and 410 within 
cytochrome b-c1 complex subunit 1, cysteine 192 within cytochrome b-c1 
complex subunit 2 and cysteine 51 with cytochrome b-c1 subunit Rieske will 
provide insight into whether nitrated cLA adducts to thiols within complex III. 
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Alternatively, linoleic acid is a major component of cardiolipin which is essential 
for complex III activity and mitochondrial supercomplex formation. Lipid 
peroxidation of linoleic acid within cardiolipin has been associated with 
decreased complex III activity and super complex formation (157). Due to 
structural similarities between cLA and lineolic acid, the nitration of cLA may 
mimic the lipid peroxidation effect of linoleic acid leading to the decreased 
complex III activity via supercomplex formation. The assessment of 
supercomplex formation by blue native PAGE following cLA and nitrite treatment 
would provide insight into mitochondrial structural architecture changes that 
regulate complex III activity.   
 Additionally, the assessment of hydrogen peroxide levels in freshly 
isolated mitochondria following MI would yield a stronger link between decreased 
complex III activity and hydrogen peroxide levels. The addition of antimycin A to 
isolated mitochondria that have undergone MI would decrease elevated complex 
III activity thereby lowering hydrogen peroxide levels. This would provide a 
mechanistic link between complex III activity and hydrogen peroxide levels 
following MI.  
 The combination treatment of cLA and nitrite increases protein expression 
of HO-1, and HO-1 is a Nrf2 regulated gene. The regulation of complex III activity 
and hydrogen peroxide levels could potentially play a role in activating Nrf2 via 
redox dependent inactivation and degradation of KEAP1, the negative regulator 
of Nrf2. Examining nuclear translocation of Nrf2 in cardiac tissue of mice 
following co-treatment of cLA and nitrite would further the mechanism of HO-1 
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mediated cLA and nitrite cardioprotection to include mitochondrial derived ROS 
via altered complex III activity.  
 The combination of cLA and nitrite could also be mediating protective 
against MI via several alternative pathways including shifting from oxidative 
phosphorylation to glyolytic metabolism during MI and decreasing necrosis to 
prevent infacrt expansion. During ischemia reperfusion injury due to the lack of 
oxygen cells undergo a shift in metabolism and rely on glycolysis for ATP 
production (158). As the combination treatment decreases complex II and III 
activity (Fig. 8) this could limit electron flow from the TCA cyle and beta oxidation 
into the electron transport chain leading to reductions in ATP. The shift to 
glycolysis may allow cells an apadative phase to increase ATP production via 
glycolysis thereby cells are more likey to survive an ischemic insult. To determine 
if cLA and nitrite does shift cells to a more glycolytic phenotype, the activity of 
phosphofructokinase will be assayed. Phosphofructokinase is the first committed 
step in glycolysis and would provide insight into the rate of glycolysis.   
 Necrosis occurs following depletion of ATP and results in cell death (159). 
As the combination treatment of cLA and nitrite could potential increase ATP 
production via glycolysis, this may provide a link to prevent necrosis during MI. 
By maintaining ATP levels via glycolysis during ischemia this would prevent cells 
from undergoing necrosis and reduce secondary inflammtory responses that 
occur after cell necrosis. To determine if cLA and nitrite is decreasing necrosis, 
the release of two necrosis specific markers will be assessed: peptidylprolyl 
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isomerase A and non-chromatin-binding high mobility group protein B1 (160) 
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